<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <atom:link rel="self" type="application/rss+xml" href="https://escholarship.org/uc/ucladom_oapolicydeposits/rss"/>
    <ttl>720</ttl>
    <title>Recent ucladom_oapolicydeposits items</title>
    <link>https://escholarship.org/uc/ucladom_oapolicydeposits/rss</link>
    <description>Recent eScholarship items from Open Access Policy Deposits</description>
    <pubDate>Wed, 16 Sep 2026 13:47:11 +0000</pubDate>
    <item>
      <title>What Dose of Methamphetamine Do Regular Consumers Use Daily? Estimating Oral Amphetamine Milligram Equivalents</title>
      <link>https://escholarship.org/uc/item/943871sh</link>
      <description>OBJECTIVES: The purity, accessibility, and affordability of illicit methamphetamine have increased in recent decades, which has been linked to rising rates of methamphetamine-involved overdoses, psychosis, cardiovascular events, and other health consequences. Nevertheless, information about the quantity of methamphetamine used by regular consumers has been limited, despite the potential clinical utility of exposure quantification.
METHODS: From August 2024 to April 2026, self-reported daily methamphetamine consumption was assessed among n = 94 individuals in Los Angeles County. Methamphetamine samples (n = 256) were analyzed for purity using liquid chromatography-mass spectrometry. Bioavailability by route of administration and stimulant equivalency were obtained from the literature. A simulation model leveraging bootstrapping with 1,000,000 draws was used to estimate oral amphetamine milligram equivalents (AME).
RESULTS: The average reported methamphetamine consumption was 1.09...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/943871sh</guid>
      <pubDate>Fri, 11 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Friedman, Joseph R</name>
      </author>
      <author>
        <name>Koncsol, Adam J</name>
        <uri>https://orcid.org/0000-0001-5984-2577</uri>
      </author>
      <author>
        <name>Molina, Caitlin A</name>
      </author>
      <author>
        <name>Romero, Ruby</name>
      </author>
      <author>
        <name>Feng, Jasmine</name>
      </author>
      <author>
        <name>Poimboeuf, Michelle</name>
      </author>
      <author>
        <name>Godvin, Morgan E</name>
      </author>
      <author>
        <name>Puri, Siddarth</name>
      </author>
      <author>
        <name>Marienfeld, Carla</name>
        <uri>https://orcid.org/0000-0002-3909-3318</uri>
      </author>
      <author>
        <name>Shover, Chelsea L</name>
      </author>
    </item>
    <item>
      <title>NCCN Guidelines® Insights: Survivorship, Version 3.2026.</title>
      <link>https://escholarship.org/uc/item/6d91b5cn</link>
      <description>The NCCN Guidelines for Survivorship offer guidance for health care providers who care for survivors of adult-onset cancer. These guidelines include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from cancer and its treatment and provide a framework for care coordination. They also present guidance for helping cancer survivors to enhance their wellness and maintain a healthy lifestyle. This article summarizes the panel's current recommendations and recent updates regarding anxiety, depression, distress, and trauma in cancer survivors.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6d91b5cn</guid>
      <pubDate>Thu, 10 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Peterson, Lindsay L</name>
      </author>
      <author>
        <name>McDonough, Allison L</name>
      </author>
      <author>
        <name>Ansbaugh, Shannon M</name>
      </author>
      <author>
        <name>Ariza-Heredia, Ella J</name>
      </author>
      <author>
        <name>Armenian, Saro</name>
      </author>
      <author>
        <name>Baker, K Scott</name>
      </author>
      <author>
        <name>Ballinger, Tarah J</name>
      </author>
      <author>
        <name>Cathcart-Rake, Elizabeth J</name>
      </author>
      <author>
        <name>Cohen, Stuart H</name>
      </author>
      <author>
        <name>Day, Andrew T</name>
      </author>
      <author>
        <name>Evgeniou, Evgenios</name>
      </author>
      <author>
        <name>Fairman, Nathan Paul</name>
      </author>
      <author>
        <name>Feliciano, Josephine</name>
      </author>
      <author>
        <name>Flores, Tessa Faye</name>
      </author>
      <author>
        <name>Friedman, Debra L</name>
      </author>
      <author>
        <name>Gabel, Nicolette M</name>
      </author>
      <author>
        <name>Hill-Kayser, Christine E</name>
      </author>
      <author>
        <name>Hock, Karen</name>
      </author>
      <author>
        <name>Kline-Quiroz, Cristina</name>
      </author>
      <author>
        <name>Lee, Nita K</name>
      </author>
      <author>
        <name>Mooney, Kathi</name>
      </author>
      <author>
        <name>Moore, Halle CF</name>
      </author>
      <author>
        <name>Moryl, Natalie</name>
      </author>
      <author>
        <name>Neuman, Heather</name>
      </author>
      <author>
        <name>Overholser, Linda</name>
      </author>
      <author>
        <name>Patel, Chirayu G</name>
      </author>
      <author>
        <name>Porpiglia, Andrea</name>
      </author>
      <author>
        <name>Rogers, Laura Q</name>
      </author>
      <author>
        <name>Saidain, Ava</name>
      </author>
      <author>
        <name>Schapira, Lidia</name>
      </author>
      <author>
        <name>Smith, Sophia K</name>
      </author>
      <author>
        <name>Tenner, Laura</name>
      </author>
      <author>
        <name>Von Ah, Diane</name>
      </author>
      <author>
        <name>Yang, Eric H</name>
        <uri>https://orcid.org/0000-0003-4889-7454</uri>
      </author>
      <author>
        <name>Zee, Phyllis</name>
      </author>
      <author>
        <name>Freedman-Cass, Deborah</name>
      </author>
      <author>
        <name>McMillian, Nicole</name>
      </author>
    </item>
    <item>
      <title>Unpacking “High-Risk”: A Latent Class Analysis of Sexual Partnership Patterns and HIV Transmission Risk Among Gay, Bisexual, and Other Men Who Have Sex With Men in Perú</title>
      <link>https://escholarship.org/uc/item/5ds1r85d</link>
      <description>BACKGROUND: Gay, bisexual, and other men who have sex with men (GBMSM) are often considered a homogenous "high-risk" group. We aimed to differentiate subgroups based on participants' last sexual partner and explore associations with HIV transmission risk factors.
SETTING: We utilized cross-sectional data (06/2022 to 03/2023) from "high-risk" GBMSM in Lima, Perú.
METHODS: Participants included cisgender men and gender nonconforming adults assigned male at birth reporting condomless anal sex with ≥1 serodiscordant or unknown serostatus cisgender man or transgender woman in the past 6 months. Latent class analysis was performed using the last sexual partner characteristics, including partner type, sexual role, and condomless anal sex position. Multinomial logistic regression examined HIV risk factors associated with latent classes, including drug use, transactional sex, sexually transmitted infection diagnosis, sexual identity, hazardous alcohol use, and number of anonymous partners.
RESULTS:...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5ds1r85d</guid>
      <pubDate>Thu, 10 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Forer, Reni</name>
      </author>
      <author>
        <name>Clark, Jesse L</name>
      </author>
      <author>
        <name>Gutierrez, Jessica</name>
      </author>
      <author>
        <name>Segura, Eddy R</name>
      </author>
      <author>
        <name>Valladares, Rolando</name>
      </author>
      <author>
        <name>Castro, Jose L</name>
      </author>
      <author>
        <name>Kumar, Narendar</name>
      </author>
      <author>
        <name>Lake, Jordan E</name>
      </author>
      <author>
        <name>Cabello, Robinson</name>
      </author>
      <author>
        <name>Blair, Cheríe S</name>
      </author>
    </item>
    <item>
      <title>Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083</title>
      <link>https://escholarship.org/uc/item/4zm660vm</link>
      <description>BACKGROUND: Sexually transmitted infections (STIs) have been shown to facilitate human immunodeficiency virus (HIV) transmission and acquisition. HPTN 083, a global clinical trial, demonstrated superiority of long-acting cabotegravir (CAB-LA) versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV prevention among transgender women and cisgender men who have sex with men. This analysis assessed whether CAB-LA maintained protective efficacy when bacterial STIs (syphilis, rectal/urethral gonorrhea, and chlamydia) were present.
METHODS: STI events per 100 person-years were calculated, including by subgroups (age, race/ethnicity, gender, education, treatment arm, drug use, alcohol use, region/country, condom usage, partner number, marital status, baseline STI). Association between baseline factors and STI incidence was modeled using Poisson regression. Cox proportional hazards modeling with STI status as a time-varying covariate was used to evaluate potential...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4zm660vm</guid>
      <pubDate>Thu, 10 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Clement, Meredith E</name>
      </author>
      <author>
        <name>Hanscom, Brett</name>
      </author>
      <author>
        <name>Haines, Daniel</name>
      </author>
      <author>
        <name>Bazan, Jose A</name>
      </author>
      <author>
        <name>Chotirosniramit, Nuntisa</name>
      </author>
      <author>
        <name>Kofron, Ryan</name>
      </author>
      <author>
        <name>Mannheimer, Sharon</name>
      </author>
      <author>
        <name>Mayer, Kenneth H</name>
      </author>
      <author>
        <name>Silva, Mayara Secco Torres</name>
      </author>
      <author>
        <name>Soto-Torres, Lydia</name>
      </author>
      <author>
        <name>Rinehart, Alex R</name>
      </author>
      <author>
        <name>Rooney, James F</name>
      </author>
      <author>
        <name>Jennings, Andrea</name>
      </author>
      <author>
        <name>Gomez-Feliciano, Kailazarid</name>
      </author>
      <author>
        <name>McCauley, Marybeth</name>
      </author>
      <author>
        <name>Grinsztejn, Beatriz</name>
      </author>
      <author>
        <name>Landovitz, Raphael J</name>
      </author>
      <author>
        <name>Abdalian, Sue Ellen</name>
      </author>
      <author>
        <name>Arduino, Roberto C</name>
      </author>
      <author>
        <name>Bazan, Jose</name>
      </author>
      <author>
        <name>Boyer, Juan Carlos Hinojosa</name>
      </author>
      <author>
        <name>Cabello, Robinson</name>
      </author>
      <author>
        <name>Chariyalertsak, Suwat</name>
      </author>
      <author>
        <name>Clark, Jesse</name>
      </author>
      <author>
        <name>del Rio, Carlos</name>
      </author>
      <author>
        <name>Dunne, Eileen F</name>
      </author>
      <author>
        <name>Fichtenbaum, Carl</name>
      </author>
      <author>
        <name>Frank, Ian</name>
      </author>
      <author>
        <name>Franks, Julie</name>
      </author>
      <author>
        <name>Gallardo-Cartagena, Jorge A</name>
      </author>
      <author>
        <name>Gaur, Aditya</name>
      </author>
      <author>
        <name>Gonzales, Pedro</name>
      </author>
      <author>
        <name>Grinsztejn, Beatriz</name>
      </author>
      <author>
        <name>Gulick, Roy</name>
      </author>
      <author>
        <name>Ha, Tran Viet</name>
      </author>
      <author>
        <name>Hall, Christopher</name>
      </author>
      <author>
        <name>Huamani, Javier Antonio Valencia</name>
      </author>
      <author>
        <name>Hurt, Christopher</name>
      </author>
      <author>
        <name>Justman, Jessica</name>
      </author>
      <author>
        <name>Kallas, Esper G</name>
      </author>
      <author>
        <name>Kelley, Colleen</name>
      </author>
      <author>
        <name>Landovitz, Raphael J</name>
      </author>
      <author>
        <name>Liu, Albert</name>
      </author>
      <author>
        <name>Losso, Marcelo H</name>
      </author>
      <author>
        <name>Madruga, José Valdez Ramalho</name>
      </author>
      <author>
        <name>Magnus, Manya</name>
      </author>
      <author>
        <name>Mayer, Kenneth</name>
      </author>
      <author>
        <name>Middelkoop, Keren</name>
      </author>
      <author>
        <name>Novak, Richard</name>
      </author>
      <author>
        <name>Overton, E Turner</name>
      </author>
      <author>
        <name>Oyedele, Temitope</name>
      </author>
      <author>
        <name>Phanuphak, Nittaya</name>
      </author>
      <author>
        <name>Presti, Rachel</name>
      </author>
      <author>
        <name>Reirden, Daniel</name>
      </author>
      <author>
        <name>Rompalo, Anne</name>
      </author>
      <author>
        <name>Santos, Breno Riegel</name>
      </author>
      <author>
        <name>Sued, Omar</name>
      </author>
      <author>
        <name>Swaminathan, Shobha</name>
      </author>
      <author>
        <name>van Dam, Cornelius</name>
      </author>
    </item>
    <item>
      <title>Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.</title>
      <link>https://escholarship.org/uc/item/4jq2k0fr</link>
      <description>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity and diabetes management, with rapidly expanding indications and use among U.S. adults. Despite their promise, key questions remain about optimal treatment pathways, long-term safety, effectiveness across diverse populations, adherence, and economic impact. Real-world evidence (RWE) derived from electronic health records, claims, and other data sources could address these gaps, but unique challenges complicate its use, such as inconsistent insurance coverage, high discontinuation rates, medication shortages, compounded formulations, and off-label prescribing. To explore these issues, the National Institute of Diabetes and Digestive and Kidney Diseases convened a workshop in May 2025 with experts from regulatory agencies, guideline committees, payers, and academia. Discussions focused on identifying knowledge gaps in GLP-1RA use, evaluating how RWE informs practice, assessing limitations of real-world...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4jq2k0fr</guid>
      <pubDate>Thu, 10 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Arterburn, David</name>
      </author>
      <author>
        <name>Curtis, Lesley H</name>
      </author>
      <author>
        <name>Toh, Sengwee</name>
      </author>
      <author>
        <name>Bradley, Marie C</name>
      </author>
      <author>
        <name>D'Alessio, David</name>
      </author>
      <author>
        <name>Duchovny, Noelia</name>
      </author>
      <author>
        <name>Hines, David</name>
      </author>
      <author>
        <name>Narain, Kimberly</name>
      </author>
      <author>
        <name>Parekh, Anand</name>
      </author>
      <author>
        <name>Skinner, Asheley</name>
      </author>
      <author>
        <name>Wee, Christina C</name>
      </author>
      <author>
        <name>Wong, John B</name>
      </author>
      <author>
        <name>Wright, Davene R</name>
      </author>
      <author>
        <name>Osganian, Stavroula K</name>
      </author>
      <author>
        <name>Hales, Craig</name>
      </author>
    </item>
    <item>
      <title>Dopamine signaling drives skin invasion by human-infective nematodes</title>
      <link>https://escholarship.org/uc/item/2c6566rh</link>
      <description>Skin-penetrating nematodes are one of the most prevalent causes of disease worldwide. The World Health Organization has targeted these parasites for elimination by 2030, but the lack of preventative measures is a major obstacle to this goal. Infective larvae enter hosts through skin and blocking skin penetration could prevent infection. However, in order to prevent worm ingress via the skin, an understanding of the behavioral and neural mechanisms that drive skin penetration is required. Here, we describe the skin-penetration behavior of the human-infective threadworm Strongyloides stercoralis. We show that S. stercoralis engages in repeated cycles of pushing, puncturing, and crawling on the skin surface before penetrating. Pharmacological inhibition of dopamine signaling inhibits these behaviors in S. stercoralis and the human hookworm Ancylostoma ceylanicum, suggesting a critical role for dopamine signaling in driving skin penetration across distantly related nematodes. CRISPR-mediated...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2c6566rh</guid>
      <pubDate>Thu, 10 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Patel, Ruhi</name>
      </author>
      <author>
        <name>Bartolo, Gloria</name>
      </author>
      <author>
        <name>Castelletto, Michelle L</name>
        <uri>https://orcid.org/0009-0001-1366-3669</uri>
      </author>
      <author>
        <name>Garcia Romero, Aracely</name>
      </author>
      <author>
        <name>Bryant, Astra S</name>
      </author>
      <author>
        <name>Agak, George W</name>
        <uri>https://orcid.org/0000-0002-3356-9864</uri>
      </author>
      <author>
        <name>Hallem, Elissa A</name>
        <uri>https://orcid.org/0000-0003-0260-3174</uri>
      </author>
    </item>
    <item>
      <title>Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer Current Evidence and Evolving Considerations: JACC: CardioOncology Primer</title>
      <link>https://escholarship.org/uc/item/15f8b4qw</link>
      <description>Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer Current Evidence and Evolving Considerations: JACC: CardioOncology Primer</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/15f8b4qw</guid>
      <pubDate>Thu, 10 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Moore, Heather</name>
      </author>
      <author>
        <name>Huppert, Laura A</name>
      </author>
      <author>
        <name>Moslehi, Javid J</name>
      </author>
      <author>
        <name>Yang, Eric H</name>
        <uri>https://orcid.org/0000-0003-4889-7454</uri>
      </author>
      <author>
        <name>Hatcher, Sarah</name>
      </author>
      <author>
        <name>Thomas, Alexandra</name>
      </author>
    </item>
    <item>
      <title>Practice Pattern and Outcome Differences in the Emergency Department by Physician Sex</title>
      <link>https://escholarship.org/uc/item/5v7695nv</link>
      <description>Practice Pattern and Outcome Differences in the Emergency Department by Physician Sex</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5v7695nv</guid>
      <pubDate>Wed, 9 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Ly, Dan P</name>
        <uri>https://orcid.org/0000-0001-5760-0208</uri>
      </author>
      <author>
        <name>Coussens, Stephen</name>
      </author>
      <author>
        <name>Burke, Laura G</name>
      </author>
    </item>
    <item>
      <title>Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research</title>
      <link>https://escholarship.org/uc/item/0ct6m0m5</link>
      <description>PURPOSE OF REVIEW: This review highlights the role of the gastrointestinal (GI) microbiome in systemic sclerosis (SSc). We describe techniques for evaluating the GI microbiome in humans, and emerging research linking GI microbiome alterations (i.e., dysbiosis) and distinct SSc clinical manifestations. We also address the evolving treatment landscape targeting dysbiosis in SSc.
RECENT FINDINGS: Recent literature brings into focus the complex relationship between the GI microbiome and SSc pathogenesis. Advanced techniques (e.g., shotgun metagenomics, meta-transcriptomics) provide deeper insights into microbial taxonomy and active gene expression, exposing dysbiosis as a potential driver of SSc. New studies demonstrate that SSc patients who possess specific SSc clinical features, (e.g., interstitial lung disease), have unique GI microbiome profiles.
SUMMARY: Dysbiosis is associated with specific clinical features in patients with SSc. New tools for studying the GI microbiome have...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0ct6m0m5</guid>
      <pubDate>Sun, 6 Sep 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Haussmann, Alana J</name>
      </author>
      <author>
        <name>McMahan, Zsuzsanna H</name>
      </author>
      <author>
        <name>Volkmann, Elizabeth R</name>
        <uri>https://orcid.org/0000-0003-3750-6569</uri>
      </author>
    </item>
    <item>
      <title>Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy</title>
      <link>https://escholarship.org/uc/item/5fd4g4bz</link>
      <description>BACKGROUND: Older women are underrepresented in hereditary cancer guidelines, and the prevalence of pathogenic or likely pathogenic (P/LP) germline variants in ovarian cancer (OC) patients aged ≥70 remains poorly characterized. Current recommendations for risk-reducing interventions and surveillance rely heavily on variant and family history (FH), yet their applicability in older populations is uncertain. We evaluated age-stratified prevalence of P/LP variants at OC diagnosis to identify at-risk older patients and inform more inclusive genetic counseling strategies.
METHODS: We conducted a retrospective analysis of 113,236 OC patients undergoing germline testing through the Myriad Collaborative Research Registry (1996-2024). Variant prevalence, ancestry, FH, and testing patterns were evaluated across age groups, with focus on patients ≥70.
RESULTS: Overall, 14,513 patients (12.8%) harbored a P/LP variant, including 13,049 (11.5%) in established OC susceptibility genes. Among patients...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5fd4g4bz</guid>
      <pubDate>Thu, 27 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Shachar, Eliya</name>
      </author>
      <author>
        <name>Rotkop, Gilat</name>
      </author>
      <author>
        <name>Haas, Roni</name>
      </author>
      <author>
        <name>Frankenthal, Rachel</name>
      </author>
      <author>
        <name>Kamara, Daniella</name>
      </author>
      <author>
        <name>Demirjian, Maral</name>
      </author>
      <author>
        <name>Kwan, Lorna</name>
      </author>
      <author>
        <name>Cummings, Shelly</name>
      </author>
      <author>
        <name>Roscow, Breanna</name>
      </author>
      <author>
        <name>Salani, Ritu</name>
      </author>
      <author>
        <name>Spellman, Paul T</name>
        <uri>https://orcid.org/0000-0002-4810-0022</uri>
      </author>
      <author>
        <name>Karlan, Beth</name>
        <uri>https://orcid.org/0000-0002-9451-2933</uri>
      </author>
      <author>
        <name>Chase, Dana M</name>
      </author>
    </item>
    <item>
      <title>Ligandability at the Membrane Interface of GPx4 Revealed through a Reverse Micelle Fragment Screening Platform.</title>
      <link>https://escholarship.org/uc/item/5bs3k8fv</link>
      <description>While they account for a large portion of drug targets, membrane proteins present a unique challenge for drug discovery. Peripheral membrane proteins (PMPs), a class of water-soluble proteins that bind to membranes, are also difficult targets, particularly those that function only when bound to membranes. The protein-membrane interface in PMPs is often where functional interactions and catalysis occur, making it a logical target for inhibition. However, protein-membrane interfaces are underexplored spaces in inhibitor design, and there is a need for enhanced methods for small-molecule ligand discovery. In an effort to better initiate drug discovery efforts for PMPs, this study presents a screening methodology using membrane-mimicking reverse micelles (mmRM) and NMR-based fragment screening to assess ligandability at the protein-membrane interface. The proof-of-principle target, glutathione peroxidase 4 (GPx4), is a lipid hydroperoxidase that is essential for the oxidative protection...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5bs3k8fv</guid>
      <pubDate>Thu, 27 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Labrecque, Courtney</name>
      </author>
      <author>
        <name>Fuglestad, Brian</name>
      </author>
    </item>
    <item>
      <title>Time-restricted feeding enhances cross-tissue temporal coordination of mitochondrial-associated transcripts</title>
      <link>https://escholarship.org/uc/item/98w198rb</link>
      <description>Coordinating metabolism with the day-night cycle is essential for health. Circadian rhythms synchronize cellular and tissue functions with the external environment. Nutrient timing is a potent circadian cue that entrains peripheral clocks across organs. Mitochondria exhibit daily rhythms in energy metabolism and redox regulation; however, the temporal organization of mitochondrial-associated transcriptional programs across tissues remains unknown. We hypothesized that time-restricted feeding (TRF) enhances the cross-tissue coordination of mitochondrial-associated transcripts (MATs). Using a 22-tissue, 24-h transcriptomic dataset from mice under &lt;i&gt;ad libitum&lt;/i&gt; or TRF conditions, we applied correlation- and phase-based analyses to quantify the intra- and inter-tissue alignment of MAT expression. TRF markedly increased cross-tissue coordination, nearly quadrupling the number of globally aligned MATs. Among these, &lt;i&gt;Coq10b&lt;/i&gt; emerged as the most rhythmically aligned gene across...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/98w198rb</guid>
      <pubDate>Wed, 26 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Sarver, Dylan C</name>
      </author>
      <author>
        <name>Maddahi, Yaniv</name>
      </author>
      <author>
        <name>Colwell, Christopher S</name>
      </author>
      <author>
        <name>Lusis, Aldons Jake</name>
        <uri>https://orcid.org/0000-0001-9013-0228</uri>
      </author>
    </item>
    <item>
      <title>On the Misuse of Virus-Transformed Human Corneal Epithelial Cells as Surrogates for Normal Cells</title>
      <link>https://escholarship.org/uc/item/958602wz</link>
      <description>Research in corneal biology and pathology including disease modeling and drug testing largely depends on the availability of human ex vivo cultures. Because normal corneal epithelium can be cultured only for several passages, stable epithelial cell lines transformed by different agents or spontaneously have been developed. Telomerase immortalized diploid cell lines introduced more recently were shown to recapitulate traits of normal cells including the expression of some markers and stratification ability. At the same time, there are frequently used cell lines generated by transformation with viruses. The most popular lines were shown to be unstable, tetraploid, lacking important epithelial markers, having aberrant differentiation and deviating from normal cells by gene expression patterns. This perspective reviews properties of various corneal epithelial cell lines and cautions against the use of virally transformed, especially tumorigenic cell lines, as seriously deviating form...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/958602wz</guid>
      <pubDate>Wed, 26 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Ljubimov, Alexander V</name>
        <uri>https://orcid.org/0000-0003-2398-5319</uri>
      </author>
      <author>
        <name>Shah, Ruchi</name>
      </author>
    </item>
    <item>
      <title>Improving Medication Reconciliation at Discharge: A Cross-Sectional Survey.</title>
      <link>https://escholarship.org/uc/item/5gb608h2</link>
      <description>&lt;h4&gt;Background&lt;/h4&gt;Medication discrepancies remain a persistent patient safety concern despite decades of quality improvement efforts. Research indicates that about half of hospitalized adults experience at least one such discrepancy after discharge, often stemming from unclear clinician roles and poor communication among nurses, physicians, and pharmacists. Understanding nurses' perspectives is critical to designing interventions that will improve medication reconciliation and enhance patient safety at discharge.&lt;h4&gt;Purpose&lt;/h4&gt;This study aimed to explore RNs' perspectives of medication reconciliation during hospital discharge, focusing on barriers, communication patterns, and opportunities for system improvement.&lt;h4&gt;Methods&lt;/h4&gt;A cross-sectional survey was administered to nursing staff across medical telemetry, cardiac observation, short-stay, and general observation units at a large quaternary academic teaching hospital between March 21 and April 30, 2022. The survey assessed...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5gb608h2</guid>
      <pubDate>Wed, 26 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Sengupta, Sachi</name>
      </author>
      <author>
        <name>La, Jordan</name>
      </author>
      <author>
        <name>Kuppinger, Skyllar</name>
      </author>
      <author>
        <name>Quezada, Alejandro</name>
      </author>
      <author>
        <name>Wang, Stella</name>
      </author>
      <author>
        <name>Sharqawi, Zaina</name>
      </author>
      <author>
        <name>Fabian, Andre A</name>
      </author>
      <author>
        <name>Nguyen, Bianca</name>
      </author>
      <author>
        <name>Namavar, Aram A</name>
      </author>
      <author>
        <name>Dermenchyan, Anna</name>
      </author>
    </item>
    <item>
      <title>Facile strategy enabling both high loading and high release amounts of the water-insoluble drug clofazimine using mesoporous silica nanoparticles</title>
      <link>https://escholarship.org/uc/item/8620s89n</link>
      <description>Facile strategy enabling both high loading and high release amounts of the water-insoluble drug clofazimine using mesoporous silica nanoparticles</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8620s89n</guid>
      <pubDate>Fri, 21 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Chen, Wei</name>
      </author>
      <author>
        <name>Cheng, Chi-An</name>
      </author>
      <author>
        <name>Lee, Bai-Yu</name>
      </author>
      <author>
        <name>Clemens, Daniel</name>
      </author>
      <author>
        <name>Huang, Wen-Yen</name>
      </author>
      <author>
        <name>Horwitz, Marcus</name>
        <uri>https://orcid.org/0000-0001-6525-7147</uri>
      </author>
      <author>
        <name>Zink, Jeffrey</name>
      </author>
    </item>
    <item>
      <title>Photothermal Nanoblades for Delivery of Large-Sized Cargo into Mammalian Cells at High Throughput</title>
      <link>https://escholarship.org/uc/item/7z27s1rv</link>
      <description>Technologies for transferring large-sized cargo into mammalian cells are needed to advance key applications in cell engineering. However, reliable methodologies for introducing large-sized cargo into mammalian cells are nearly completely lacking. This talk will present two new technologies, photothermal nanoblade and BLAST, that overcome the size limitation of cargo delivery into mammalian cells.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7z27s1rv</guid>
      <pubDate>Fri, 21 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Wu, Vi-Chien</name>
      </author>
      <author>
        <name>Santra, Tuhin</name>
      </author>
      <author>
        <name>Wu, Ting-Hsiang</name>
      </author>
      <author>
        <name>Clemens, Daniel L</name>
      </author>
      <author>
        <name>Lee, Bai-Yu</name>
      </author>
      <author>
        <name>Wen, Ximiao</name>
      </author>
      <author>
        <name>Horwitz, Marcus A</name>
        <uri>https://orcid.org/0000-0001-6525-7147</uri>
      </author>
      <author>
        <name>Teitell, Michael A</name>
      </author>
      <author>
        <name>Chiou, Pei Yu</name>
      </author>
    </item>
    <item>
      <title>Discovery and cryoEM structure of FPM13, a periplasmic metalloprotein unique to Francisella</title>
      <link>https://escholarship.org/uc/item/93x66505</link>
      <description>We report the identification and cryoEM structure of the Francisella protein FTN_1118, a previously uncharacterized 13 kDa periplasmic protein unique to the Francisella genus. The protein was serendipitously discovered during purification of Francisella type VI secretion system (T6SS) effector proteins and is hereby designated as FPM13 (Francisella Periplasmic Metalloprotein, 13 kDa) based on its cellular and biochemical properties. Identified by the cryoID approach based on our cryoEM density map, FPM13 exists naturally as a cylindrical 18-mer complex with 9-fold dihedral symmetry, formed by stacking two donut-shaped nonamers head-to-head. Measuring ~8 nm in height and outer diameter with a 3.5 nm central channel, the complex features a double-layered wall comprising an inner β-sheet core and an outer α-helical shell. Each FPM13 monomer adopts a compact fold comprising an N-terminus β-strand, an α-helix and two additional β strands at the C-terminus. Inter-ring loop interactions,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/93x66505</guid>
      <pubDate>Thu, 20 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Clemens, Daniel L</name>
      </author>
      <author>
        <name>Lee, Bai-Yu</name>
      </author>
      <author>
        <name>Liu, Xiaoyu</name>
      </author>
      <author>
        <name>Zhou, Z Hong</name>
      </author>
      <author>
        <name>Horwitz, Marcus A</name>
        <uri>https://orcid.org/0000-0001-6525-7147</uri>
      </author>
    </item>
    <item>
      <title>Examining Undergraduates’ Intentions to Pursue a Science Career: A Longitudinal Study of a National Biomedical Training Initiative</title>
      <link>https://escholarship.org/uc/item/8xh2662t</link>
      <description>Disparities in the participation of individuals from historically excluded groups in science careers persist, particularly at advanced career stages. In response to this challenge, the National Institutes of Health developed the BUilding Infrastructure Leading to Diversity (BUILD) initiative, aimed at undergraduate institutions to examine evidence-based strategies to engage and retain students across science-related fields. In this longitudinal study, we used propensity score matching and mixed-effects logistic regression models to examine the effects of BUILD on undergraduates' intentions to pursue science-related research careers. The results indicate that students who participated in BUILD are four times more likely to pursue a science-related research career in comparison to their non-BUILD counterparts. We also discuss and present the need to incorporate research training and mentorship to promote a diverse scientific workforce.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8xh2662t</guid>
      <pubDate>Fri, 14 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Srinivasan, Jayashri</name>
      </author>
      <author>
        <name>Cobian, Krystle P</name>
      </author>
      <author>
        <name>Ramos, Hector V</name>
      </author>
      <author>
        <name>Christie, Christina A</name>
      </author>
      <author>
        <name>Crespi, Catherine M</name>
      </author>
      <author>
        <name>Seeman, Teresa</name>
      </author>
    </item>
    <item>
      <title>Institutionalizing grant-funded interventions: a multiple case study examining long-term investments in science, technology, engineering, mathematics, and medicine (STEMM)</title>
      <link>https://escholarship.org/uc/item/6gk6m2fn</link>
      <description>Background, context, and purposeAlthough funding agencies make large investments and encourage program adoption, little is known about the process of institutionalizing grant-funded efforts in higher education. This multiple case study examined how grant-funded awardees of a biomedical training grant worked toward institutionalizing program activities. Cases included 10 diverse postsecondary institutions (368 study participants) across the United States charged with implementing a federal grant aimed at comprehensive and multi-level approaches to engage and retain students from diverse backgrounds in biomedical research.FindingsEmploying prior frameworks on institutionalization in higher education, we examined how embedded campus agents appealed to two determinants of institutionalization: compatibility and mutualism. We identified institutional resources as an additional determinant. Compatibility is most commonly sought after as early as the grant proposal stage, while agents...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6gk6m2fn</guid>
      <pubDate>Fri, 14 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Cobian, Krystle P</name>
      </author>
      <author>
        <name>Stephen, Naomi A</name>
      </author>
      <author>
        <name>Ramos, Hector</name>
      </author>
      <author>
        <name>Romero, Ana L</name>
        <uri>https://orcid.org/0000-0003-1973-6635</uri>
      </author>
      <author>
        <name>Hurtado, Sylvia</name>
      </author>
      <author>
        <name>Ortiz, Denise</name>
      </author>
    </item>
    <item>
      <title>Correlates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort</title>
      <link>https://escholarship.org/uc/item/4zk4h80v</link>
      <description>Importance: Many psychiatric outcomes share a common etiologic pathway reflecting behavioral disinhibition, generally referred to as externalizing (EXT) disorders. Recent genome-wide association studies (GWASs) have demonstrated the overlap between EXT disorders and important aspects of veterans' health, such as suicide-related behaviors and substance use disorders (SUDs).
Objective: To explore correlates of risk for EXT disorders within the Veterans Health Administration (VA) Million Veteran Program (MVP).
Design, Setting, and Participants: A series of phenome-wide association studies (PheWASs) of polygenic risk scores (PGSs) for EXT disorders was conducted using electronic health records. First, ancestry-specific PheWASs of EXT PGSs were conducted in the African, European, and Hispanic or Latin American ancestries. Next, a conditional PheWAS, covarying for PGSs of comorbid psychiatric problems (depression, schizophrenia, and suicide attempt; European ancestries only), was performed....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4zk4h80v</guid>
      <pubDate>Fri, 14 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Barr, Peter B</name>
      </author>
      <author>
        <name>Bigdeli, Tim B</name>
      </author>
      <author>
        <name>Meyers, Jacquelyn L</name>
      </author>
      <author>
        <name>Peterson, Roseann E</name>
      </author>
      <author>
        <name>Sanchez-Roige, Sandra</name>
        <uri>https://orcid.org/0000-0001-6137-5699</uri>
      </author>
      <author>
        <name>Mallard, Travis T</name>
      </author>
      <author>
        <name>Dick, Danielle M</name>
      </author>
      <author>
        <name>Harden, K Paige</name>
      </author>
      <author>
        <name>Wilkinson, Anna</name>
      </author>
      <author>
        <name>Graham, David P</name>
      </author>
      <author>
        <name>Nielsen, David A</name>
      </author>
      <author>
        <name>Swann, Alan C</name>
      </author>
      <author>
        <name>Lipsky, Rachele K</name>
      </author>
      <author>
        <name>Kosten, Thomas R</name>
      </author>
      <author>
        <name>Aslan, Mihaela</name>
      </author>
      <author>
        <name>Harvey, Philip D</name>
      </author>
      <author>
        <name>Kimbrel, Nathan A</name>
      </author>
      <author>
        <name>Beckham, Jean C</name>
      </author>
      <author>
        <name>Aslan, Mihaela</name>
      </author>
      <author>
        <name>Antonelli, M</name>
      </author>
      <author>
        <name>de Asis, M</name>
      </author>
      <author>
        <name>Bauer, MS</name>
      </author>
      <author>
        <name>Brophy, Mary</name>
      </author>
      <author>
        <name>Concato, John</name>
      </author>
      <author>
        <name>Cunningham, F</name>
      </author>
      <author>
        <name>Freedman, R</name>
      </author>
      <author>
        <name>Gaziano, Michael</name>
      </author>
      <author>
        <name>Gleason, Theresa</name>
      </author>
      <author>
        <name>Harvey, Philip</name>
      </author>
      <author>
        <name>Huang, Grant</name>
      </author>
      <author>
        <name>Kelsoe, J</name>
      </author>
      <author>
        <name>Kosten, Thomas</name>
      </author>
      <author>
        <name>Lehner, T</name>
      </author>
      <author>
        <name>Lohr, JB</name>
      </author>
      <author>
        <name>Marder, SR</name>
      </author>
      <author>
        <name>Miller, P</name>
      </author>
      <author>
        <name>O Leary, Timothy</name>
      </author>
      <author>
        <name>Patterson, T</name>
      </author>
      <author>
        <name>Peduzzi, P</name>
      </author>
      <author>
        <name>Przygodski, Ronald</name>
      </author>
      <author>
        <name>Siever, Larry</name>
      </author>
      <author>
        <name>Sklar, P</name>
      </author>
      <author>
        <name>Strakowski, S</name>
      </author>
      <author>
        <name>Zhao, Hongyu</name>
      </author>
      <author>
        <name>Fanous, Ayman</name>
      </author>
      <author>
        <name>Farwell, W</name>
      </author>
      <author>
        <name>Malhorta, A</name>
      </author>
      <author>
        <name>Mane, S</name>
      </author>
      <author>
        <name>Palacios, P</name>
      </author>
      <author>
        <name>Bigdeli, Tim</name>
      </author>
      <author>
        <name>Corsey, M</name>
      </author>
      <author>
        <name>Zaluda, L</name>
      </author>
      <author>
        <name>Johnson, Juanita</name>
      </author>
      <author>
        <name>Sueiro, Melyssa</name>
      </author>
      <author>
        <name>Cavaliere, D</name>
      </author>
      <author>
        <name>Jeanpaul, V</name>
      </author>
      <author>
        <name>Maffucci, Alysia</name>
      </author>
      <author>
        <name>Mancini, L</name>
      </author>
      <author>
        <name>Deen, J</name>
      </author>
      <author>
        <name>Muldoon, G</name>
      </author>
      <author>
        <name>Whitbourne, Stacey</name>
      </author>
      <author>
        <name>Canive, J</name>
      </author>
      <author>
        <name>Adamson, L</name>
      </author>
      <author>
        <name>Calais, L</name>
      </author>
      <author>
        <name>Fuldauer, G</name>
      </author>
      <author>
        <name>Kushner, R</name>
      </author>
      <author>
        <name>Toney, G</name>
      </author>
      <author>
        <name>Lackey, M</name>
      </author>
      <author>
        <name>Mank, A</name>
      </author>
      <author>
        <name>Mahdavi, N</name>
      </author>
      <author>
        <name>Villarreal, G</name>
      </author>
      <author>
        <name>Muly, EC</name>
      </author>
      <author>
        <name>Amin, F</name>
      </author>
      <author>
        <name>Dent, M</name>
      </author>
      <author>
        <name>Wold, J</name>
      </author>
      <author>
        <name>Fischer, B</name>
      </author>
      <author>
        <name>Elliott, A</name>
      </author>
      <author>
        <name>Felix, C</name>
      </author>
      <author>
        <name>Gill, G</name>
      </author>
      <author>
        <name>Parker, PE</name>
      </author>
      <author>
        <name>Logan, C</name>
      </author>
      <author>
        <name>McAlpine, J</name>
      </author>
      <author>
        <name>DeLisi, LE</name>
      </author>
      <author>
        <name>Reece, SG</name>
      </author>
      <author>
        <name>Hammer, MB</name>
      </author>
      <author>
        <name>Agbor-Tabie, D</name>
      </author>
      <author>
        <name>Goodson, W</name>
      </author>
      <author>
        <name>Aslam, M</name>
      </author>
      <author>
        <name>Grainger, M</name>
      </author>
      <author>
        <name>Richtand, Neil</name>
      </author>
      <author>
        <name>Rybalsky, Alexander</name>
      </author>
      <author>
        <name>Al Jurdi, R</name>
      </author>
      <author>
        <name>Boeckman, E</name>
      </author>
      <author>
        <name>Natividad, T</name>
      </author>
      <author>
        <name>Smith, D</name>
      </author>
      <author>
        <name>Stewart, M</name>
      </author>
      <author>
        <name>Torres, S</name>
      </author>
      <author>
        <name>Zhao, Z</name>
      </author>
      <author>
        <name>Mayeda, A</name>
      </author>
      <author>
        <name>Green, A</name>
      </author>
    </item>
    <item>
      <title>Community PrEP delivery preferences among pregnant and breastfeeding women using oral PrEP in south africa and kenya.</title>
      <link>https://escholarship.org/uc/item/9b48k8vf</link>
      <description>OBJECTIVE: We evaluated preferences for differentiated service delivery of oral pre-exposure prophylaxis (PrEP) versus clinic pick-up among oral PrEP-experienced pregnant and breastfeeding women (PBFW) in South Africa and Kenya.
DESIGN AND METHODS: From September 2021 to February 2022, we surveyed PBFW in oral PrEP studies in South Africa and Kenya. We asked participants about their PrEP delivery preferences and used logistic regression models adjusted for age and country to identify predictors of preferring community over clinic-based PrEP delivery.
RESULTS: We surveyed 394 South African and Kenyan PBFW (73% postpartum, median age 28 years). Overall, 59.5% of South African participants (n = 113) and 24.5% of Kenyan participants (n = 50, p &amp;lt; 0.01) were interested in community PrEP delivery, most frequently due to convenience (n = 80, 49.1%) and lower transportation costs (n = 78, 47.9%). Participants preferred clinic PrEP pick-up due to privacy (n = 174, 75.3%) and desire to...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9b48k8vf</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Wara, Nafisa J</name>
      </author>
      <author>
        <name>Mvududu, Rufaro</name>
      </author>
      <author>
        <name>Marwa, Mary M</name>
      </author>
      <author>
        <name>Gómez, Laurén</name>
      </author>
      <author>
        <name>Mashele, Nyiko</name>
      </author>
      <author>
        <name>Orrell, Catherine</name>
      </author>
      <author>
        <name>Kinuthia, John</name>
      </author>
      <author>
        <name>John-Stewart, Grace</name>
      </author>
      <author>
        <name>Myer, Landon</name>
      </author>
      <author>
        <name>Hoffman, Risa</name>
      </author>
      <author>
        <name>Pintye, Jillian</name>
      </author>
      <author>
        <name>Davey, Dvora L Joseph</name>
      </author>
    </item>
    <item>
      <title>Preferences and Acceptability for Long-Acting PrEP Agents Among Pregnant and Postpartum Women with Experience Using Daily Oral PrEP in South Africa and Kenya</title>
      <link>https://escholarship.org/uc/item/6fh3x4rw</link>
      <description>Abstract  Introduction Long-acting pre-exposure prophylaxis (PrEP) options could overcome some barriers to oral PrEP persistence during pregnancy and postpartum. We evaluated long-acting PrEP preferences among oral PrEP-experienced pregnant and postpartum women in South Africa and Kenya, two countries with high coverage of oral PrEP and with pending regulatory approvals for long-acting injectable cabotegravir and the dapivirine vaginal ring (approved in South Africa, under review in Kenya).   Methods From September 2021 to February 2022, we surveyed pregnant and postpartum women enrolled in oral PrEP studies in South Africa and Kenya. We evaluated oral PrEP attitudes and preferences for existing and future long-acting PrEP methods.   Results We surveyed 190 women in South Africa (67% postpartum; median age 27 years [IQR 22-32]) and 204 women in Kenya (79% postpartum; median age 29 years [IQR 25-33]). 75% of participants reported oral PrEP use within the last 30 days. Overall,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6fh3x4rw</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Wara, Nafisa J</name>
      </author>
      <author>
        <name>Mvududu, Rufaro</name>
      </author>
      <author>
        <name>Marwa, Mary M</name>
      </author>
      <author>
        <name>Gómez, Laurén</name>
      </author>
      <author>
        <name>Mashele, Nyiko</name>
      </author>
      <author>
        <name>Orrell, Catherine</name>
      </author>
      <author>
        <name>Moucheraud, Corrina</name>
        <uri>https://orcid.org/0000-0001-7862-7928</uri>
      </author>
      <author>
        <name>Kinuthia, John</name>
      </author>
      <author>
        <name>John-Stewart, Grace</name>
      </author>
      <author>
        <name>Myer, Landon</name>
      </author>
      <author>
        <name>Hoffman, Risa</name>
      </author>
      <author>
        <name>Pintye, Jillian</name>
      </author>
      <author>
        <name>Davey, Dvora L Joseph</name>
      </author>
    </item>
    <item>
      <title>Advancing the inclusion of pregnant and lactating populations in HIV PrEP research: ethical, regulatory, and surveillance recommendations from a multisectoral working group.</title>
      <link>https://escholarship.org/uc/item/4jd566dc</link>
      <description>Despite a 60% decline in new HIV infections since 1995, significant challenges persist. In 2023, 1.3 million new HIV infections occurred, with 645,500 in sub-Saharan Africa, where cisgender adolescent girls and women represent over two-thirds of new cases. Approximately one-quarter of vertical HIV transmissions are linked to infections during pregnancy and lactation, yet data on PrEP use in these populations remains generally limited due to their exclusion from clinical trials, despite a recent movement toward inclusion, such as in the PURPOSE 1 trials evaluating the efficacy and safety of lenacapavir. This data gap is concerning given that women face an elevated risk of HIV acquisition during pregnancy. Despite this heightened risk, access to PrEP remains restricted among these groups. This article, based on insights from a multi-regional and multi-sectoral working group convened by the Forum for Collaborative Research between January 2024 and February 2025, addresses this critical...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4jd566dc</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Osakwe, CE</name>
      </author>
      <author>
        <name>Schaefer, R</name>
      </author>
      <author>
        <name>Donaldson, L</name>
      </author>
      <author>
        <name>Abiodun, AS</name>
      </author>
      <author>
        <name>Chatani-Gada, M</name>
      </author>
      <author>
        <name>Chigome, AK</name>
      </author>
      <author>
        <name>Day, S</name>
      </author>
      <author>
        <name>Deaton, C</name>
      </author>
      <author>
        <name>Elemuwa, UG</name>
      </author>
      <author>
        <name>Ingold, H</name>
      </author>
      <author>
        <name>Joseph Davey, D</name>
        <uri>https://orcid.org/0000-0001-6290-9293</uri>
      </author>
      <author>
        <name>Kersey, K</name>
      </author>
      <author>
        <name>Lamprianou, S</name>
      </author>
      <author>
        <name>Lyerly, AD</name>
      </author>
      <author>
        <name>Noguchi, LM</name>
      </author>
      <author>
        <name>Nyambayo, PPM</name>
      </author>
      <author>
        <name>Mpaso, C</name>
      </author>
      <author>
        <name>Robertson, MN</name>
      </author>
      <author>
        <name>Renaud, F</name>
      </author>
      <author>
        <name>Sehloho, T</name>
      </author>
      <author>
        <name>van Wyk, J</name>
      </author>
      <author>
        <name>Vannappagari, V</name>
      </author>
      <author>
        <name>Warren, M</name>
      </author>
      <author>
        <name>Miller, V</name>
      </author>
      <author>
        <name>Long-Acting PrEP during Pregnancy and Lactation Working Group</name>
      </author>
    </item>
    <item>
      <title>Enabled self-care for HIV infection: an inflection point for sustainable epidemic control</title>
      <link>https://escholarship.org/uc/item/46d450tj</link>
      <description>Enabled self-care for HIV infection: an inflection point for sustainable epidemic control</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/46d450tj</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Joseph Davey, Dvora</name>
        <uri>https://orcid.org/0000-0001-6290-9293</uri>
      </author>
    </item>
    <item>
      <title>Factors influencing implementation of point-of-care tests for maternal and newborn screening and diagnosis in low-resource settings: a systematic review</title>
      <link>https://escholarship.org/uc/item/34m6x4zb</link>
      <description>BackgroundDespite the potential of point-of-care (POC) tests to improve maternal and newborn health, implementation in low- and middle-income countries remains inconsistent. POC testing enables rapid, decentralized screening, but barriers across health system, facility, and individual levels may undermine uptake. This review synthesizes evidence on factors influencing the adoption, implementation, and sustainability of POC tests within maternal-child health programmes in low-resourced settings.MethodsA comprehensive search was performed across major bibliographic databases and grey literature sources using Boolean combinations of terms related to POC testing, maternal and newborn health, implementation, and low-resourced settings. Studies were eligible if they reported on adoption, implementation, or sustainability of POC tests for maternal or infant screening or diagnosis in low-resourced contexts. Data were extracted using a structured form capturing study characteristics, test...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/34m6x4zb</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Shaetonhodi, Natalie Grace</name>
      </author>
      <author>
        <name>de Vos, Lindsey</name>
      </author>
      <author>
        <name>Brock, Peya</name>
      </author>
      <author>
        <name>Davey, Dvora Joseph</name>
      </author>
      <author>
        <name>de Voux, Alex</name>
      </author>
      <author>
        <name>Medina-Marino, Andrew</name>
      </author>
    </item>
    <item>
      <title>Advancing ethical biomedical HIV prevention research for pregnant and lactating people</title>
      <link>https://escholarship.org/uc/item/2zq9n9dm</link>
      <description>Advancing ethical biomedical HIV prevention research for pregnant and lactating people</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2zq9n9dm</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Sullivan, Kristen</name>
      </author>
      <author>
        <name>Chatani-Gada, Manju</name>
      </author>
      <author>
        <name>Lievense, Breanne</name>
      </author>
      <author>
        <name>Slack, Catherine</name>
      </author>
      <author>
        <name>Abrams, Elaine</name>
      </author>
      <author>
        <name>Bunge, Katherine</name>
      </author>
      <author>
        <name>Stranix-Chibanda, Lynda</name>
      </author>
      <author>
        <name>Crawley, Francis P</name>
      </author>
      <author>
        <name>Das, Moupali</name>
      </author>
      <author>
        <name>Davey, Dvora Joseph</name>
      </author>
      <author>
        <name>Ghazaryan, Lusine</name>
      </author>
      <author>
        <name>Hattas, Yumnah</name>
      </author>
      <author>
        <name>Muturi-Kioi, Vincent</name>
      </author>
      <author>
        <name>Nhamo, Definate</name>
      </author>
      <author>
        <name>Noguchi, Lisa</name>
      </author>
      <author>
        <name>Richards, Khadija</name>
      </author>
      <author>
        <name>Vicari, Marissa</name>
      </author>
      <author>
        <name>Warren, Mitchell</name>
      </author>
      <author>
        <name>Lyerly, Anne Drapkin</name>
      </author>
    </item>
    <item>
      <title>Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings</title>
      <link>https://escholarship.org/uc/item/2ns2x95j</link>
      <description>PURPOSE OF REVIEW: Recent research on efficacy and safety of long-acting preexposure prophylaxis (PrEP) holds the promise to transform HIV prevention in high HIV burden settings. We review emerging findings regarding early end-user acceptability of long-acting PrEP modalities, feasibility of integrating long-acting PrEP into health systems, and considerations regarding drug resistance and cost.
RECENT FINDINGS: Long-acting PrEP, particularly injectables, was found to be highly acceptable among individuals across key populations in high HIV burden settings. Concerns around use of long-acting PrEP highlight the importance of choice and ability to switch methods. Existing provider-level barriers to oral PrEP implementation (e.g., overburdened staff, training gaps) may impact long-acting PrEP rollout - however, utilization of PrEP implementation strategies such as task-shifting, timely PrEP training for all providers, differentiated service delivery, and integration with sexual health...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2ns2x95j</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Davey, Dvora Joseph</name>
      </author>
      <author>
        <name>Dadan, Sumaya</name>
      </author>
      <author>
        <name>Wara, Nafisa</name>
      </author>
    </item>
    <item>
      <title>Intersecting Vulnerabilities: Depression, Suicidality, and HIV Risk Among Young Mothers in South Africa</title>
      <link>https://escholarship.org/uc/item/2kz2b61q</link>
      <description>Many African women who are pregnant or parenting face intersecting challenges including intimate partner violence, unplanned pregnancies, and motherhood-related stresses that heighten vulnerability to poor mental health. Depression and suicidal ideation are associated with behaviors that increase HIV risk, yet limited research has explored these relationships in African contexts. This study examined associations between depressive symptoms, suicidal ideation, and sexual risk behaviors among unemployed young women aged 19–24 years in KwaZulu-Natal, South Africa. Baseline data were collected between June-October 2018 from participants who had been sexually active in the past year. Prolonged sadness (≥ 2 weeks) and suicidal ideation in the past year were measured using validated single-item indicators. The composite HIV risk outcome captured transactional sex, partners with unknown HIV/STI status, and substance-influenced sex. Poisson regression models adjusted for age, intimate...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2kz2b61q</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Miller, AP</name>
      </author>
      <author>
        <name>Joseph Davey, DL</name>
        <uri>https://orcid.org/0000-0001-6290-9293</uri>
      </author>
      <author>
        <name>Groenewald, C</name>
      </author>
      <author>
        <name>Filiatreau, LM</name>
      </author>
      <author>
        <name>Petersen, Z</name>
      </author>
      <author>
        <name>van Rooyen, H</name>
      </author>
      <author>
        <name>Essack, Z</name>
      </author>
    </item>
    <item>
      <title>Participatory Prototyping of a Tailored Undetectable Equals Untransmittable Message to Increase HIV Testing Among Men in Western Cape, South Africa</title>
      <link>https://escholarship.org/uc/item/1v9122hr</link>
      <description>Daily antiretroviral therapy (ART) suppresses viral replication, rendering HIV undetectable through viral load (VL) testing. People living with HIV (PLWH) who have an undetectable VL cannot transmit HIV to sexual partners or through giving birth, a message commonly referred to as U = U (undetectable equals untransmittable). To increase knowledge and understanding of U = U among men, who have poorer HIV testing and treatment outcomes than women, we engaged men from high HIV burden communities in Cape Town in two interactive human-centered design cocreation workshops to develop local U = U messaging for men. Two trained workshop facilitators, explained the U = U message to 39 adult men (in two separate workshops), and asked them how to effectively communicate U = U to other men in the local language (isiXhosa). Participant-designed messages sought to inform men about U = U to help assuage fears of testing HIV positive (by removing the stigma of living with HIV and being a vector...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1v9122hr</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Smith, Philip J</name>
      </author>
      <author>
        <name>Davey, Dvora L Joseph</name>
      </author>
      <author>
        <name>Schmucker, Laura</name>
      </author>
      <author>
        <name>Bruns, Cal</name>
      </author>
      <author>
        <name>Bekker, Linda-Gail</name>
      </author>
      <author>
        <name>Medina-Marino, Andrew</name>
      </author>
      <author>
        <name>Thirumurthy, Harsha</name>
      </author>
      <author>
        <name>Buttenheim, Alison M</name>
      </author>
    </item>
    <item>
      <title>Long-term use of ART in African women of reproductive age</title>
      <link>https://escholarship.org/uc/item/1ms4x80t</link>
      <description>Long-term use of ART in African women of reproductive age</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1ms4x80t</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Davey, Dvora Joseph</name>
      </author>
    </item>
    <item>
      <title>Exploration of Pregnant and Breastfeeding Women’s Acceptability of Rapid Point-of-Care Urine Testing Within Antenatal and Postnatal Care, and Its Perceived Impact on PrEP Adherence When Paired with PrEP Biofeedback Adherence Counselling in Cape Town, South Africa</title>
      <link>https://escholarship.org/uc/item/1dv378sr</link>
      <description>Pregnant and breastfeeding women (PBFW) on oral pre-exposure prophylaxis (PrEP) face barriers to adherence and persistence which may be improved by point-of-care adherence monitoring using urine tenofovir testing. We explored the acceptability of urine tenofovir testing for PrEP adherence monitoring among PBFW on oral PrEP, and how this, together with PrEP biofeedback adherence counselling, may have shaped PBFW’s PrEP adherence and persistence. Between September 2022 and May 2024, we conducted a study among PBFW without HIV on oral PrEP in Cape Town, South Africa. Participants were randomized to intervention (urine tenofovir testing at each study visit with biofeedback adherence counselling) or standard-of-care arms (urine collected but not analyzed with participant, with standard PrEP adherence counselling). Participants, with consistent and inconsistent PrEP use, were purposively sampled from both study arms between October and December 2023 for qualitative interviews. Analysis...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1dv378sr</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Court, Lara</name>
      </author>
      <author>
        <name>Mvududu, Rufaro</name>
      </author>
      <author>
        <name>Schoetz Dean, Sarah</name>
      </author>
      <author>
        <name>Knight, Lucia</name>
      </author>
      <author>
        <name>Dovel, Kathryn</name>
      </author>
      <author>
        <name>Gandhi, Monica</name>
      </author>
      <author>
        <name>Myer, Landon</name>
      </author>
      <author>
        <name>Coates, Thomas</name>
      </author>
      <author>
        <name>Joseph Davey, Dvora L</name>
        <uri>https://orcid.org/0000-0001-6290-9293</uri>
      </author>
    </item>
    <item>
      <title>Prevalence, symptomology, and correlates of curable sexually transmitted infections among pregnant women in Eastern Cape, South Africa</title>
      <link>https://escholarship.org/uc/item/12s2c373</link>
      <description>BackgroundCurable sexually transmitted infections (STIs) contribute to adverse maternal and neonatal outcomes. Syndromic management is standard care in South Africa. We evaluated prevalence, symptomology, and correlates of curable STIs, among pregnant women in Eastern Cape, South Africa.MethodsWe conducted a cross-sectional analysis using baseline data from a randomized controlled trial of pregnant women attending their first antenatal care visit at public clinics in Buffalo City Municipality (2021-2024). Participants were tested for &lt;i&gt;Chlamydia (C.) trachomatis&lt;/i&gt;, &lt;i&gt;Neisseria (N.) gonorrhoeae&lt;/i&gt;, &lt;i&gt;Trichomonas (T.) vaginalis&lt;/i&gt; using GeneXpert point-of-care tests and for syphilis using Alere Determine TP rapid test. Symptoms were self-reported and clinically-observed. Adjusted prevalence ratios were estimated using Poisson regression models with robust standard errors.ResultsAmong 1491 participants (median age: 28 years (IQR: 24-33); gestational age: 13 weeks (IQR: 8-18);...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/12s2c373</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Shaetonhodi, Natalie G</name>
      </author>
      <author>
        <name>de Voux, Alex</name>
      </author>
      <author>
        <name>Babalola, Chibuzor M</name>
      </author>
      <author>
        <name>Davey, Dvora Joseph</name>
      </author>
      <author>
        <name>Mdingi, Mandisa M</name>
      </author>
      <author>
        <name>Gigi, Ranjana MS</name>
      </author>
      <author>
        <name>Peters, Remco PH</name>
      </author>
      <author>
        <name>Mukomana, Freedom</name>
      </author>
      <author>
        <name>Klausner, Jeffrey D</name>
      </author>
      <author>
        <name>Medina-Marino, Andrew</name>
      </author>
    </item>
    <item>
      <title>Community-Based Adaptation and Evaluation of a Peer-Led Intervention to Address Alcohol Use and HIV in Pregnant and Breastfeeding Women in South Africa: Protocol for the “Mentor Mothers Plus” Randomized Control Trial</title>
      <link>https://escholarship.org/uc/item/0r94z2k2</link>
      <description>BACKGROUND: In South Africa, pregnant and lactating women (PLW) face a dual burden of high alcohol use and HIV prevalence, both of which adversely affect maternal and infant health. However, few interventions address alcohol use and HIV risk concurrently in this population.
OBJECTIVE: This study seeks to adapt and pilot-test in a randomized controlled trial (RCT) the peer-led multisession intervention Mentor Mothers Plus (MM+) to integrate alcohol reduction strategies with HIV prevention and care support (in a seroneutral intervention) among PLW in Saldanha Bay, Western Cape, South Africa.
METHODS: Using the ADAPT-ITT (assessment, decision, adaptation, production, topical experts, integration, training, testing) framework, we adapted the evidence-based Mentor Mother (MM) model, originally aimed at reducing vertical HIV transmission among mothers with HIV. Our mixed methods design includes (1) qualitative research, including in-depth interviews (IDIs) and focus group discussions...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0r94z2k2</guid>
      <pubDate>Thu, 13 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Essack, Zaynab</name>
      </author>
      <author>
        <name>Petersen, Zaino</name>
      </author>
      <author>
        <name>Miller, Amanda P</name>
      </author>
      <author>
        <name>Dean, Sarah Schoetz</name>
      </author>
      <author>
        <name>Daniels, Danielle</name>
      </author>
      <author>
        <name>Hofmeester, Hayley</name>
      </author>
      <author>
        <name>Belin, Thomas</name>
      </author>
      <author>
        <name>van Rooyen, Heidi</name>
      </author>
      <author>
        <name>Louw, Jaco</name>
      </author>
      <author>
        <name>Davey, Dvora Joseph</name>
      </author>
    </item>
    <item>
      <title>Dashboard-Directed Intervention to Improve Guideline-Directed Heart Failure Therapy for Veterans</title>
      <link>https://escholarship.org/uc/item/96d35280</link>
      <description>BACKGROUND: Significant gaps in guideline-directed medical therapy (GDMT) persist in patients with heart failure (HF) with reduced ejection fraction (HFrEF). Although population health dashboards can identify these gaps, sustainable workflows integrating them into routine practice remain largely underutilized.
OBJECTIVES: This study aimed to evaluate the implementation and outcomes of a dashboard-based intervention in a novel clinical-educational hybrid model aimed to improve GDMT use.
METHODS: From July 2024 to June 2025, a weekly, half-day HF Dashboard Population Health Clinic was implemented at a single Veterans Affairs center. A supervised team of cardiology fellows and nurse practitioners performed medical record reviews of patients with gaps in GDMT identified on the Veterans Affairs HF Dashboard, with a focus on underutilization of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in HFrEF patients. Clinicians executed targeted telehealth interventions, initiated therapies,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/96d35280</guid>
      <pubDate>Wed, 12 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Sheng, Qicong</name>
        <uri>https://orcid.org/0000-0003-3034-8772</uri>
      </author>
      <author>
        <name>Brownell, Nicholas K</name>
        <uri>https://orcid.org/0000-0001-8156-0808</uri>
      </author>
      <author>
        <name>Hsu, Jeffrey J</name>
      </author>
      <author>
        <name>Chang, Donald S</name>
      </author>
      <author>
        <name>Fonarow, Gregg C</name>
        <uri>https://orcid.org/0000-0002-3192-8093</uri>
      </author>
      <author>
        <name>Ziaeian, Boback</name>
        <uri>https://orcid.org/0000-0001-9787-3649</uri>
      </author>
    </item>
    <item>
      <title>Cefepime resistance with preserved ceftriaxone susceptibility in Proteus mirabilis osteomyelitis associated with bla OXA-1 gene amplification: Two case reports with genomic analysis</title>
      <link>https://escholarship.org/uc/item/49n1q77j</link>
      <description>Objective Retrospective case series to describe an unusual cefepime-resistant, ceftriaxone-susceptible phenotype in Proteus mirabilis osteomyelitis associated with bla OXA-1 gene amplification. Patients Two adult patients with diabetes mellitus and chronic osteomyelitis, one with diabetic foot ulcer and one with infected hip prosthesis, both with prolonged antibiotic treatment. Methods Clinical data and antimicrobial susceptibility results were reviewed. Whole-genome sequencing was performed using short-read and long-read platforms with hybrid assembly. Resistance gene identification, phylogenetic analysis, and gene copy number estimation were conducted. Results Three isolates of P. mirabilis from two patients demonstrated an unusual phenotype of cefepime resistance (MIC 16–32 μg/mL) with susceptibility to ceftriaxone. Hybrid assembly and coverage analysis demonstrated amplification of the bla OXA-1-containing cassette, with approximately 16- and 24-fold duplication in patient...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/49n1q77j</guid>
      <pubDate>Wed, 12 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Lima, Amorce</name>
      </author>
      <author>
        <name>Collins, Mackenzie</name>
      </author>
      <author>
        <name>Jaramillo, Mario</name>
      </author>
      <author>
        <name>Gonzalez-Ferrer, Shekina</name>
      </author>
      <author>
        <name>Sircar, Anita</name>
      </author>
      <author>
        <name>Allyn, Paul R</name>
        <uri>https://orcid.org/0000-0002-3659-8732</uri>
      </author>
      <author>
        <name>Yang, Shangxin</name>
        <uri>https://orcid.org/0000-0001-9991-1178</uri>
      </author>
    </item>
    <item>
      <title>Sisyphean Task of Cardiovascular Prevention: Real Gains, Unequal Progress</title>
      <link>https://escholarship.org/uc/item/1dz43132</link>
      <description>Sisyphean Task of Cardiovascular Prevention: Real Gains, Unequal Progress</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1dz43132</guid>
      <pubDate>Wed, 12 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Ziaeian, Boback</name>
        <uri>https://orcid.org/0000-0001-9787-3649</uri>
      </author>
      <author>
        <name>Fonarow, Gregg C</name>
        <uri>https://orcid.org/0000-0002-3192-8093</uri>
      </author>
    </item>
    <item>
      <title>Cost Offset With Quadruple Therapy for Heart Failure.</title>
      <link>https://escholarship.org/uc/item/0v1313b1</link>
      <description>Importance: Contemporary guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), which includes angiotensin receptor-neprilysin inhibitors (ARNI), β-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i), reduces hospitalizations in randomized clinical trials (RCTs), but the combined economic impact of implementing full quadruple therapy after hospitalization is not well quantified.
Objective: To estimate the 1-year health care cost offset and net cost associated with implementation of quadruple GDMT after hospitalization for HFrEF.
Design, Setting, and Participants: This economic evaluation used Medicare-linked data from the American Heart Association's Get With The Guidelines-Heart Failure (GWTG-HF) registry to identify adults 65 years or older hospitalized with HFrEF from 2016 to 2020 with up to 1-year postdischarge follow-up. Data were analyzed from November 2025 to February...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0v1313b1</guid>
      <pubDate>Wed, 12 Aug 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Keykhaei, Mohammad</name>
      </author>
      <author>
        <name>Rashedi, Sina</name>
      </author>
      <author>
        <name>Greene, Stephen J</name>
      </author>
      <author>
        <name>Yancy, Clyde</name>
      </author>
      <author>
        <name>Ziaeian, Boback</name>
        <uri>https://orcid.org/0000-0001-9787-3649</uri>
      </author>
      <author>
        <name>Sandhu, Alexander T</name>
      </author>
      <author>
        <name>Kittleson, Michelle</name>
      </author>
      <author>
        <name>Fonarow, Gregg C</name>
        <uri>https://orcid.org/0000-0002-3192-8093</uri>
      </author>
    </item>
    <item>
      <title>Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology</title>
      <link>https://escholarship.org/uc/item/9m2278hj</link>
      <description>BackgroundHydroxyurea (HU) is a first-line oral cytoreductive agent for selected patients with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), due to its efficacy and tolerability. Although cutaneous ulceration is a recognized complication of long-term HU exposure, HU-associated digital gangrene is rare, and upper-extremity involvement in PV has not previously been reported.Case presentationWe describe the first case of HU-associated digital gangrene in a patient with PV. A 72-year-old man with well-controlled Janus kinase 2 (JAK2)–positive PV, treated with HU for more than a decade, developed painless dry gangrene of the right index and middle fingers. Vascular imaging showed no significant arterial occlusion or embolic source. Hematologic parameters remained within target ranges, and the workup for autoimmune disease, infection, and hypercoagulability was unremarkable. HU was discontinued, and the ischemia stabilized without surgical intervention. With...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9m2278hj</guid>
      <pubDate>Thu, 30 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Misic, Angela</name>
      </author>
      <author>
        <name>Ghanem, Ghadi</name>
        <uri>https://orcid.org/0000-0002-3139-7050</uri>
      </author>
      <author>
        <name>Sadeghi, Saeed</name>
      </author>
      <author>
        <name>Carroll, Matthew</name>
      </author>
    </item>
    <item>
      <title>Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.</title>
      <link>https://escholarship.org/uc/item/96b5r70w</link>
      <description>PURPOSE: This phase Ib dose-escalation/expansion trial (NCT03400176) enrolled patients with CLL who did not achieve a complete response (CR) with ibrutinib or had developed resistance mutations.&amp;nbsp;Ianalumab (VAY736), an anti-B cell-activating factor receptor monoclonal antibody, combined with ibrutinib significantly improved survival and reduced tumor burden in preclinical chronic lymphocytic leukemia (CLL) models.
PATIENTS AND METHODS: Patients received intravenous ianalumab (escalation: 0.3-9.0 mg/kg; expansion: 3.0 mg/kg) once every 2 weeks and continued ibrutinib (420 mg) once daily for up to eight cycles of 28 days. The study aimed to evaluate the safety, tolerability, recommended dose, and antitumor activity of this combination.
RESULTS: Thirty-nine patients were treated (escalation: n = 15; expansion: n = 24). No dose-limiting toxicities were observed. Of the 39 patients, 38.5% were in CR or CR with incomplete marrow recovery at cycle 9 (C9). At C9 day 1, 17 patients...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/96b5r70w</guid>
      <pubDate>Thu, 30 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Rogers, Kerry A</name>
      </author>
      <author>
        <name>Yan, Pearlly</name>
      </author>
      <author>
        <name>Flinn, Ian W</name>
      </author>
      <author>
        <name>Stephens, Deborah M</name>
      </author>
      <author>
        <name>Kipps, Thomas J</name>
        <uri>https://orcid.org/0000-0002-0064-4549</uri>
      </author>
      <author>
        <name>Larson, Sarah M</name>
      </author>
      <author>
        <name>Martz, Laura</name>
      </author>
      <author>
        <name>Chen, Xi</name>
      </author>
      <author>
        <name>Wang, Huabao</name>
      </author>
      <author>
        <name>Hopping, Ethan</name>
      </author>
      <author>
        <name>Bundschuh, Ralf</name>
      </author>
      <author>
        <name>Turkoglu, Altan</name>
      </author>
      <author>
        <name>Lozanski, Gerard</name>
      </author>
      <author>
        <name>McGarry, Carolyn</name>
      </author>
      <author>
        <name>Acosta, Alexandra</name>
      </author>
      <author>
        <name>Sechaud, Romain</name>
      </author>
      <author>
        <name>Baldoni, Daniela</name>
      </author>
      <author>
        <name>Chaudhury, Anwesha</name>
      </author>
      <author>
        <name>Whalen, Jeanne</name>
      </author>
      <author>
        <name>Hassounah, Nadia B</name>
      </author>
      <author>
        <name>Orwitz, Nina</name>
      </author>
      <author>
        <name>Otero, Javier</name>
      </author>
      <author>
        <name>Woo, Janghee</name>
      </author>
      <author>
        <name>Byrd, John C</name>
      </author>
    </item>
    <item>
      <title>Psychiatric Hospitalization Precipitants and Outcomes in a Comprehensive Dementia Care Program</title>
      <link>https://escholarship.org/uc/item/7wc0k536</link>
      <description>OBJECTIVES: Characterize the precipitants and outcomes of psychiatric hospitalizations among patients enrolled in a comprehensive dementia care program and identify factors associated with discharge to higher-level residential setting.
DESIGN: Retrospective cohort study.
SETTING: UCLA Alzheimer's and Dementia Care Program.
PARTICIPANTS: Patients hospitalized at the UCLA Resnick Neuropsychiatric Hospital (NPH).
MEASUREMENTS: Precipitating reasons for hospitalization, patient demographic and clinical characteristics, hospitalization-level characteristics, and caregiver relationship. Discharge to higher-level residential settings (e.g., assisted living, nursing home). Change in scheduled Central Nervous System (CNS)-active medications (antipsychotics, antidepressants, and sedative/hypnotics).
RESULTS: There were 180 psychiatric hospitalizations among 150 patients, with a median age of 79 years (IQR, 73-85) at admission and MMSE score of 17 (IQR, 12-24) at first hospitalization. Agitation...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7wc0k536</guid>
      <pubDate>Thu, 30 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Lee, David R</name>
        <uri>https://orcid.org/0000-0003-2052-6192</uri>
      </author>
      <author>
        <name>Endo, Andrew S</name>
      </author>
      <author>
        <name>Kalbasi, Tahmineh R</name>
      </author>
      <author>
        <name>Turner, Maurice</name>
      </author>
      <author>
        <name>Jimenez, Ivette A</name>
      </author>
      <author>
        <name>Serrano, Katherine Sy</name>
      </author>
      <author>
        <name>Centeno, Andrea</name>
      </author>
      <author>
        <name>Reuben, David B</name>
      </author>
    </item>
    <item>
      <title>The effectiveness of care coordination on medication adherence among high-need, high-cost commercially insured beneficiaries: A randomized controlled trial</title>
      <link>https://escholarship.org/uc/item/6ps928mx</link>
      <description>&lt;h4&gt;Background&lt;/h4&gt;High-need, high-cost (HNHC) beneficiaries experience life stressors that complicate their medication self-management. Care coordination programs may improve medication-taking behavior, including for chronic conditions that require daily medication adherence.&lt;h4&gt;Objective&lt;/h4&gt;To determine whether nurse-led care coordination is associated with improved adherence among an HNHC commercial population with a chronic condition.&lt;h4&gt;Methods&lt;/h4&gt;We analyzed data from a pragmatic, national randomized controlled trial of a comprehensive care coordination program conducted by a large national insurer and assessed its impacts on medication adherence in diabetes, atrial fibrillation, and hypothyroidism. We performed intention-to-treat (ITT) analyses (primary) and instrumental variable (IV) analyses (secondary) for HNHC beneficiaries from 2019 through 2022. Analyses compared treatment of control arms for metformin in diabetes (n = 3,602), statins in diabetes (n = 3,938), direct...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6ps928mx</guid>
      <pubDate>Wed, 29 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Saju, Rintu</name>
      </author>
      <author>
        <name>Harwood, Jessica M</name>
      </author>
      <author>
        <name>Tseng, Chi-Hong</name>
      </author>
      <author>
        <name>Moin, Tannaz</name>
      </author>
      <author>
        <name>Mangione, Carol</name>
        <uri>https://orcid.org/0000-0002-9475-2275</uri>
      </author>
      <author>
        <name>Takada, Sae</name>
      </author>
      <author>
        <name>Onufrak, Stephen</name>
      </author>
      <author>
        <name>Duru, Kenrik</name>
      </author>
    </item>
    <item>
      <title>Body composition changes during cardiac rehabilitation and long-term cardiovascular outcomes in patients with coronary artery disease</title>
      <link>https://escholarship.org/uc/item/0bc3m6np</link>
      <description>Aims: This study assesses whether changes in body composition - lean body mass (LBM) and body fat % (BF%) - and body mass index (BMI), in patients undergoing cardiac rehabilitation (CR), are associated with long-term outcomes.
Methods: In this cohort study of 1234 adults with coronary artery disease (CAD) who participated in CR from April 2012 to June 2024, bioelectric impedance analysis was used at baseline and after CR to assess body composition. Outcomes assessed included net adverse cardiovascular events (NACE) and all-cause mortality.
Results: Subjects were followed for a mean of 5.9&amp;nbsp;years (SD 3.2). We found that those who had an increase in BF% during CR had a higher risk of NACE (adjusted HR 1.44, 95% CI: 1.10, 1.90) compared to those who had a decrease in BF%. There was also a trend towards decreased mortality in patients with a moderate increase in LBM (adjusted HR 0.49, 95% CI 0.23, 1.02). There were no associations between changes in body mass index and any outcomes....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0bc3m6np</guid>
      <pubDate>Wed, 29 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Kumar, Aarti</name>
      </author>
      <author>
        <name>Van, Christopher</name>
      </author>
      <author>
        <name>Shahrvini, Tara</name>
      </author>
      <author>
        <name>Srikanthan, Preethi</name>
      </author>
      <author>
        <name>Horwich, Tamara B</name>
        <uri>https://orcid.org/0000-0002-3208-1023</uri>
      </author>
    </item>
    <item>
      <title>cfDNA derived gene signatures as surrogate for microvascular invasion in HCC.</title>
      <link>https://escholarship.org/uc/item/02d552jc</link>
      <description>&lt;h4&gt;Background &amp;amp; aim&lt;/h4&gt;Microvascular invasion (MVI) is a critical prognostic risk factor in hepatocellular carcinoma (HCC). This study evaluated the performance of 5-hydroxymethylcytosine (5hmC) modifications in circulating cell-free DNA (cfDNA) in preoperative assessment of MVI.&lt;h4&gt;Methods&lt;/h4&gt;A total of 907 patients with HCC were enrolled from two centers, including 671 in the training cohort, 152 in the internal validation cohort, and 84 in the external validation cohort. Preoperative clinical data, laboratory parameters, and cfDNA-derived 5hmC profiles were collected. Feature selection was performed using XGBoost, and modeling was conducted using a multilayer perceptron (MLP) neural network. Survival analyses were performed to evaluate the prognostic significance of the MVI prediction model. RNA sequencing analysis was performed to explore the potential mechanism underlying the proposed model.&lt;h4&gt;Results&lt;/h4&gt;The 181-5hmC-modification signature demonstrated strong discriminatory...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/02d552jc</guid>
      <pubDate>Wed, 29 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Gong, Ruijie</name>
      </author>
      <author>
        <name>Wang, Linchen</name>
      </author>
      <author>
        <name>Xue, Dondon</name>
      </author>
      <author>
        <name>Cai, Jiabin</name>
      </author>
      <author>
        <name>Jiang, Yurou</name>
      </author>
      <author>
        <name>Huang, Jianhang</name>
      </author>
      <author>
        <name>Zhu, Jinjin</name>
      </author>
      <author>
        <name>Li, Zhongchen</name>
      </author>
      <author>
        <name>Ke, Aiwu</name>
      </author>
      <author>
        <name>Shi, Guoming</name>
      </author>
      <author>
        <name>Wang, Jie</name>
      </author>
      <author>
        <name>Wang, Wentao</name>
      </author>
      <author>
        <name>Zheng, Jiaping</name>
      </author>
      <author>
        <name>Yang, Weijian</name>
      </author>
      <author>
        <name>Zhang, Zhou</name>
      </author>
      <author>
        <name>Zhou, Jian</name>
      </author>
      <author>
        <name>Fan, Jia</name>
      </author>
      <author>
        <name>Zhang, Wei</name>
      </author>
      <author>
        <name>Gao, Pingting</name>
      </author>
      <author>
        <name>Chen, Lei</name>
      </author>
      <author>
        <name>Song, Danjun</name>
      </author>
    </item>
    <item>
      <title>An Observational Study of Post-hip Fracture Outcomes in Older Adults with Type 2 Diabetes</title>
      <link>https://escholarship.org/uc/item/8rn8m4rp</link>
      <description>BackgroundHip fracture is a global public health concern, with over 10 million cases worldwide in 2019. Post-hip fracture outcomes, including mortality, vary by type 2 diabetes (T2D) co-diagnosis and patient demographics.ObjectiveTo examine post-hip fracture outcomes and identify factors modifying mortality differences in a racially and ethnically diverse population of older United States (US) adults with T2D.DesignRetrospective cohort study using Medicare fee-for-service data from 2014 to 2020.ParticipantsMen and women aged &amp;gt; 65&amp;nbsp;years, with T2D diagnosis who had experienced a non-traumatic hip fracture.Main Measure(s)We evaluated associations between race and ethnicity and one-year mortality, dual energy x-ray absorptiometry (DXA) testing, osteoporosis treatment, and incident destitution post-hip fracture using multivariable Cox proportional hazards models.Key ResultsAmong 159,699 older adults with T2D, one-year post-hip fracture mortality was 30.4%. In age- and sex-adjusted...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8rn8m4rp</guid>
      <pubDate>Wed, 22 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Okazaki, Keity M</name>
      </author>
      <author>
        <name>Marion, Lipi A</name>
      </author>
      <author>
        <name>Burnett-Bowie, Sherri-Ann M</name>
      </author>
      <author>
        <name>Cromer, Sara J</name>
      </author>
      <author>
        <name>Ortega-Montiel, Janinne</name>
      </author>
      <author>
        <name>Byrne, Caroline F</name>
      </author>
      <author>
        <name>Patorno, Elisabetta</name>
      </author>
      <author>
        <name>Paik, Julie M</name>
      </author>
      <author>
        <name>Yu, Elaine W</name>
      </author>
    </item>
    <item>
      <title>Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.</title>
      <link>https://escholarship.org/uc/item/7117h0vz</link>
      <description>OBJECTIVE: To evaluate the comparative effectiveness of dulaglutide or semaglutide versus tirzepatide on cardiovascular outcomes in adults with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD).
RESEARCH DESIGN AND METHODS: Two target trial emulations included commercially insured adults (June 2022-December 2024) with T2D and ASCVD who initiated subcutaneous tirzepatide, dulaglutide, or semaglutide. The primary outcome was modified major adverse cardiovascular events (MACE), defined as a composite of nonfatal myocardial infarction, nonfatal stroke, and all-cause death. First, new users of tirzepatide and dulaglutide were propensity score (PS) matched one to one. Second, new users of tirzepatide and semaglutide were PS matched one to one. Incidence rates (IRs) per 1,000 person-years and hazard ratios (HRs) were estimated.
RESULTS: After PS matching, 9,233 pairs of tirzepatide or dulaglutide initiators and 25,266 pairs of tirzepatide or semaglutide initiators...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7117h0vz</guid>
      <pubDate>Wed, 22 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Ostrominski, John W</name>
      </author>
      <author>
        <name>Ortega-Montiel, Janinne</name>
      </author>
      <author>
        <name>Wexler, Deborah J</name>
      </author>
      <author>
        <name>Everett, Brendan M</name>
      </author>
      <author>
        <name>Cromer, Sara J</name>
      </author>
      <author>
        <name>Byrne, Caroline F</name>
      </author>
      <author>
        <name>Glynn, Robert J</name>
      </author>
      <author>
        <name>Paik, Julie M</name>
      </author>
      <author>
        <name>Patorno, Elisabetta</name>
      </author>
    </item>
    <item>
      <title>Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes</title>
      <link>https://escholarship.org/uc/item/655412f1</link>
      <description>Rationale &amp;amp; Objective: Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been approved for type 2 diabetes (T2D) and obesity. However, the real-world utilization of tirzepatide remains unexplored, particularly in patients with chronic kidney disease (CKD), where the prevalence of T2D and obesity is high. This study aimed to describe the utilization trends of tirzepatide, glucose-lowering medications (GLMs), and anti-obesity medications (AOMs) in patients with CKD, with and without T2D.
Study Design: A population-based, observational cohort study.
Setting &amp;amp; Participants: Patients with CKD, with and without T2D, were identified from a large US health insurance claims database (from January 1, 2022 to September 30, 2023).
Exposures: Tirzepatide, other GLMs, and AOMs.
Outcomes: Medication utilization trends and patient characteristics. Any users were defined as those with prescription claims, and incident users as those with no previous dispensing within 365 days.
Analytical...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/655412f1</guid>
      <pubDate>Wed, 22 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Hansrivijit, Panupong</name>
      </author>
      <author>
        <name>Ortega-Montiel, Janinne</name>
      </author>
      <author>
        <name>Wexler, Deborah J</name>
      </author>
      <author>
        <name>Patorno, Elisabetta</name>
      </author>
      <author>
        <name>Paik, Julie M</name>
      </author>
    </item>
    <item>
      <title>The Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications In Patients with Type 2 Diabetes</title>
      <link>https://escholarship.org/uc/item/4ds7q5j1</link>
      <description>OBJECTIVE: Patients with type 2 diabetes (T2D) are at increased risk of acute pancreatitis (AP) and biliary events. Evidence remains mixed regarding the association between incretin-based therapies, such as glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is), and these outcomes. We examined the association between incretin medication use and risk of incident AP or biliary disease in patients with T2D.
RESEARCH DESIGN AND METHODS: Using Medicare Fee-for-Service (FFS) and two U.S. commercial claims databases (2014-2021), we identified three pairwise cohorts of propensity score (PS)-based fine stratification-weighted patients aged ≥18 years (≥65 years in Medicare FFS) with T2D without prior AP or biliary disease who initiated treatment with GLP-1RAs versus sodium-glucose cotransporter 2 inhibitors (SGLT2is), DPP-4is versus SGLT2is, or GLP-1RAs versus DPP-4is. PS was estimated using 92 covariates. Weighted hazard ratios (HRs) with 95%...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4ds7q5j1</guid>
      <pubDate>Wed, 22 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Fang, Yichen E</name>
      </author>
      <author>
        <name>Paik, Julie M</name>
      </author>
      <author>
        <name>Ortega-Montiel, Janinne</name>
      </author>
      <author>
        <name>Tesfaye, Helen</name>
      </author>
      <author>
        <name>Wexler, Deborah J</name>
      </author>
      <author>
        <name>Patorno, Elisabetta</name>
      </author>
    </item>
    <item>
      <title>Trends in Utilization of Glucose- and Weight-Lowering Medications after Tirzepatide Approval in the United States: A Population-Based Cohort Study</title>
      <link>https://escholarship.org/uc/item/0jf640k1</link>
      <description>BACKGROUND: Recent trends in use of tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptor agonist (RA), versus other glucose-lowering medications (GLMs) and weight-lowering medications (WLMs) remain unexplored.
OBJECTIVE: To describe trends in insurance claims for GLMs and WLMs after tirzepatide approval.
DESIGN: Population-based cohort study.
SETTING: Claims data from a large U.S. commercial database (January 2021 to December 2023).
PARTICIPANTS: Adults (aged ≥18 years) with type 2 diabetes (T2D) and without diabetes with dispensations for GLMs and WLMs. Any use was defined as medication dispensation regardless of prior use. Incident use was defined as dispensation without use in the preceding year.
MEASUREMENTS: Monthly trends in medication dispensations before and after tirzepatide market entry. Tirzepatide uptake was additionally compared with initial postapproval uptake of other GLMs and WLMs.
RESULTS: Tirzepatide dispensations...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0jf640k1</guid>
      <pubDate>Wed, 22 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Ostrominski, John W</name>
      </author>
      <author>
        <name>Ortega-Montiel, Janinne</name>
      </author>
      <author>
        <name>Tesfaye, Helen</name>
      </author>
      <author>
        <name>Alix, Caroline</name>
      </author>
      <author>
        <name>DiCesare, Elyse</name>
      </author>
      <author>
        <name>Cromer, Sara J</name>
      </author>
      <author>
        <name>Wexler, Deborah J</name>
      </author>
      <author>
        <name>Paik, Julie M</name>
      </author>
      <author>
        <name>Patorno, Elisabetta</name>
      </author>
    </item>
    <item>
      <title>81. Post-Treatment Imaging in Lung Cancer Patients: Adherence to Surveillance Guidelines Associated with Improved Survival in a Longitudinal Cohort</title>
      <link>https://escholarship.org/uc/item/9rn5z3x0</link>
      <description>81. Post-Treatment Imaging in Lung Cancer Patients: Adherence to Surveillance Guidelines Associated with Improved Survival in a Longitudinal Cohort</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9rn5z3x0</guid>
      <pubDate>Sun, 19 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Lin, Nicole</name>
      </author>
      <author>
        <name>Immidisetti, Amanda</name>
      </author>
      <author>
        <name>Adams, Scott</name>
      </author>
      <author>
        <name>Kapula, Ntemena</name>
      </author>
      <author>
        <name>Wu, Julie</name>
        <uri>https://orcid.org/0000-0003-2388-1827</uri>
      </author>
      <author>
        <name>Zeliadt, Steven</name>
      </author>
      <author>
        <name>Asch, Steven</name>
      </author>
      <author>
        <name>Sox-Harris, Alex</name>
      </author>
      <author>
        <name>Leung, Ann</name>
      </author>
      <author>
        <name>Han, Summer</name>
      </author>
      <author>
        <name>Backhus, Leah</name>
      </author>
    </item>
    <item>
      <title>Rule-based natural language processing to extract clinical trial and research study enrollment history from unstructured notes</title>
      <link>https://escholarship.org/uc/item/9pm5n7fj</link>
      <description>Clinical trials are vital for advancing care. However, a systematic approach to tracking trial participation across different facilities and sponsors has been lacking. We developed natural language processing (NLP) methods to extract study enrollment history, including enrollment status, consent date, and study title from information on clinical trial participation recorded in clinical notes in the electronic health record based on national Veterans Affairs electronic health record data. The method exhibited high test-set precision for enrollment status (0.94), consent date (0.97), and study title (0.87) and acceptably high recall (0.76, 0.70, and 0.84, respectively). From a single center, the classifier correctly identified 111 of 125 trial participants (88.8%) across 12 distinct trials. Our study demonstrates the feasibility of using NLP to capture trial enrollment from a nationwide healthcare system. This algorithm creates a novel data resource for analyzing and tracking trial...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9pm5n7fj</guid>
      <pubDate>Sun, 19 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Goryachev, Sergey D</name>
      </author>
      <author>
        <name>Wu, Julie Tsu-Yu</name>
        <uri>https://orcid.org/0000-0003-2388-1827</uri>
      </author>
      <author>
        <name>Lin, Eric</name>
      </author>
      <author>
        <name>Friedman, Daphne R</name>
      </author>
      <author>
        <name>Zwolinski, Robert</name>
      </author>
      <author>
        <name>Dhond, Rupali</name>
      </author>
      <author>
        <name>Elbers, Danne C</name>
      </author>
      <author>
        <name>La, Jennifer</name>
      </author>
      <author>
        <name>Yildirim, Cenk</name>
      </author>
      <author>
        <name>Corrigan, June K</name>
      </author>
      <author>
        <name>Chen, Daniel CR</name>
      </author>
      <author>
        <name>Brophy, Mary T</name>
      </author>
      <author>
        <name>V., Nhan</name>
      </author>
      <author>
        <name>Fillmore, Nathanael R</name>
      </author>
    </item>
    <item>
      <title>Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study</title>
      <link>https://escholarship.org/uc/item/7xc1k45x</link>
      <description>BackgroundLung cancer survivors have a high risk of second primary lung cancer (SPLC). While air pollution is associated with the risk of initial primary lung cancer (IPLC), especially in never smokers, its effect on SPLC risk is unknown.MethodsWe identified 2439 IPLC patients from the UK Biobank, followed through 2017, linking baseline addresses to 2005–2007 annual average exposures of particulate matter (PM10) and nitrogen dioxide (NO2) from the EU-wide Land Use Regression model. Associations with SPLC risk were assessed using cause-specific Cox models adjusted for co-pollutants, socioeconomic factors, smoking, and tumour characteristics.ResultsOf 2439 IPLC patients, 92 (3.7%) developed SPLC over 6561 person-years. The 10-year cumulative incidence of SPLC was 3.98% (3.11–4.85%). A dose-response relationship was observed between PM10 and SPLC risk, with an adjusted hazard ratio (aHR) of 6.43 (2.38–17.32) in the highest vs. lowest (aHR = 1.69 [0.68–4.19]) quintile; a co-pollutant...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7xc1k45x</guid>
      <pubDate>Sun, 19 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Choi, Eunji</name>
      </author>
      <author>
        <name>Luo, Sophia</name>
      </author>
      <author>
        <name>Ding, Victoria Y</name>
      </author>
      <author>
        <name>Graber-Nadich, Anna</name>
      </author>
      <author>
        <name>Wu, Julie T</name>
        <uri>https://orcid.org/0000-0003-2388-1827</uri>
      </author>
      <author>
        <name>Popat, Rita</name>
      </author>
      <author>
        <name>Cheng, Iona</name>
      </author>
      <author>
        <name>Neal, Joel W</name>
      </author>
      <author>
        <name>Wakelee, Heather A</name>
      </author>
      <author>
        <name>Han, Summer S</name>
      </author>
    </item>
    <item>
      <title>Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non–Small Cell Lung Cancer</title>
      <link>https://escholarship.org/uc/item/7kj2n9m1</link>
      <description>PURPOSE: As treatment options for advanced non-small cell lung cancer (NSCLC) evolve, biomarkers are needed to guide therapy selection while balancing efficacy and toxicity. Although tumor burden is a promising candidate, its prognostic role in guiding epidermal growth factor receptor (EGFR)-targeted kinase inhibitor (TKI) therapies remains understudied in real-world settings.
METHODS: We identified patients with de novo stage IV &lt;i&gt;EGFR&lt;/i&gt;-mutant NSCLC treated with first-line EGFR-TKI at Stanford Health Care (2000-2021). Tumor burden metrics were manually annotated from 592 baseline radiology reports, encompassing size, number, and location (1,807 lesions). Multivariable Cox regression evaluated associations between tumor burden metric and overall survival (OS), adjusting for confounders, in the overall cohort and an osimertinib subgroup. A weighted composite tumor burden score was constructed using statistically significant metrics to stratify risk.
RESULTS: Of 312 patients,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7kj2n9m1</guid>
      <pubDate>Sun, 19 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Terashima, Rika</name>
      </author>
      <author>
        <name>Fan, Judy</name>
      </author>
      <author>
        <name>Gunturkun, Fatma</name>
      </author>
      <author>
        <name>Nieda, Grant</name>
      </author>
      <author>
        <name>Fan, Xiaomei</name>
      </author>
      <author>
        <name>Rodriguez, Emily M</name>
      </author>
      <author>
        <name>Tan, Annabel X</name>
      </author>
      <author>
        <name>Thottunkal, Stefan</name>
      </author>
      <author>
        <name>Shaw, Maggie</name>
      </author>
      <author>
        <name>Su, Chloe C</name>
      </author>
      <author>
        <name>Khan, Aparajita</name>
      </author>
      <author>
        <name>Ding, Victoria Y</name>
      </author>
      <author>
        <name>Luo, Ingrid</name>
      </author>
      <author>
        <name>Satoyoshi, Mina</name>
      </author>
      <author>
        <name>Bhat, Archana</name>
      </author>
      <author>
        <name>Gu, Bo</name>
      </author>
      <author>
        <name>Henry, Solomon M</name>
      </author>
      <author>
        <name>Ellis-Caleo, Timothy J</name>
      </author>
      <author>
        <name>Odden, Michelle</name>
      </author>
      <author>
        <name>Kurian, Allison W</name>
      </author>
      <author>
        <name>Neal, Joel W</name>
      </author>
      <author>
        <name>Wakelee, Heather A</name>
      </author>
      <author>
        <name>Wu, Julie T</name>
        <uri>https://orcid.org/0000-0003-2388-1827</uri>
      </author>
      <author>
        <name>Han, Summer S</name>
      </author>
    </item>
    <item>
      <title>Adherence to Posttreatment Surveillance Guidelines in Non–Small Cell Lung Cancer: Retrospective Cohort Study</title>
      <link>https://escholarship.org/uc/item/46v7f3st</link>
      <description>Background: Several guidelines recommend posttreatment surveillance for non-small cell lung cancer (NSCLC). However, studies evaluating surveillance patterns often cannot distinguish between imaging ordered for surveillance versus for symptoms suggestive of recurrence. Moreover, early recurrences and other competing events hamper efforts to determine true surveillance rates because of wide variability in reported guideline adherence in clinical practice. Leveraging comprehensive Veterans Health Administration data, we developed a novel competing risks framework to describe the patterns and predictors of NSCLC imaging surveillance.
Objective: This study aims to examine posttreatment surveillance to estimate the true surveillance rates and predictors of guideline-concordant care in patients with early-stage NSCLC.
Methods: The study cohort comprised veterans who were treated for stage 1 to 3 NSCLC between 2008 and 2016 and who survived for ≥6 months. Clinical documents and radiology...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/46v7f3st</guid>
      <pubDate>Sun, 19 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Randle, Ryan J</name>
      </author>
      <author>
        <name>Adams, Scott V</name>
      </author>
      <author>
        <name>Esfahanimonfared, Zahra</name>
      </author>
      <author>
        <name>Lin, Nicole</name>
      </author>
      <author>
        <name>Wu, Julie</name>
        <uri>https://orcid.org/0000-0003-2388-1827</uri>
      </author>
      <author>
        <name>Leung, Ann</name>
      </author>
      <author>
        <name>Asch, Steven M</name>
      </author>
      <author>
        <name>Zeliadt, Steven</name>
      </author>
      <author>
        <name>Sox-Harris, Alex</name>
      </author>
      <author>
        <name>Han, Summer</name>
      </author>
      <author>
        <name>Backhus, Leah M</name>
      </author>
    </item>
    <item>
      <title>Navigating the Complexity of Lung Cancer Surveillance Practices: Qualitative Pilot Study on Provider Perspectives</title>
      <link>https://escholarship.org/uc/item/2p6124cv</link>
      <description>Background: Surveillance is noted to be an important part of survivorship to detect recurrence and/or second primary lung cancer (SPLC) at a curable stage. However, current surveillance guidelines remain controversial, and the factors providers consider in clinical decision-making are neither well-defined nor consistently applied.
Objective: In order to inform the qualitative protocol for a larger national study, this pilot study aimed to understand the factors that influence lung cancer surveillance and how providers view risk stratification as a potential tool to inform surveillance practices.
Methods: Semistructured interviews were conducted between October 2023 and July 2024 with purposively sampled providers involved in treating and surveilling patients with lung cancer from the US-based Palo Alto Veterans Affairs Medical Center and Stanford Medicine and its affiliate clinics. Providers were recruited through both email outreach and in-person invitations. Interviews were...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2p6124cv</guid>
      <pubDate>Sun, 19 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Woo, Jenny M</name>
      </author>
      <author>
        <name>Conover, Sydney</name>
      </author>
      <author>
        <name>Gray, Caroline</name>
      </author>
      <author>
        <name>Arya, Shipra</name>
      </author>
      <author>
        <name>Wu, Julie T</name>
        <uri>https://orcid.org/0000-0003-2388-1827</uri>
      </author>
    </item>
    <item>
      <title>Provider Follow-Up and Adherence to Imaging Surveillance Recommendations for Lung Cancer Survivors in a Nationwide Health Care System.</title>
      <link>https://escholarship.org/uc/item/0vb9d40h</link>
      <description>PURPOSE: With the growing number of cancer survivors and projected shortages of oncology providers, understanding who delivers survivorship care has important implications for care quality. We examined follow-up provider patterns among lung cancer survivors in the Veterans Health Administration (VHA) system and assessed variation in receipt of guideline-concordant computed tomography (CT) imaging.
METHODS: We conducted a retrospective cohort study of 20,532 Veterans with stage I to III non-small cell lung cancer who received definitive treatment between 2008 and 2016. The primary exposure was the lung cancer survivor's follow-up provider specialty, defined as the specialty with whom the patient received the most post-treatment follow-up visits. We evaluated associations between treatment type and follow-up provider specialty and compared receipt of guideline-concordant surveillance imaging, defined as chest CT performed 120-270 days after treatment, across specialties using multivariable...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0vb9d40h</guid>
      <pubDate>Sun, 19 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Wu, Julie T</name>
        <uri>https://orcid.org/0000-0003-2388-1827</uri>
      </author>
      <author>
        <name>Lin, Nicole</name>
      </author>
      <author>
        <name>Adams, Scott V</name>
      </author>
      <author>
        <name>Asch, Steven</name>
      </author>
      <author>
        <name>Zeliadt, Steven</name>
      </author>
      <author>
        <name>Harris, Alex HS</name>
      </author>
      <author>
        <name>Han, Summer S</name>
      </author>
      <author>
        <name>Backhus, Leah</name>
      </author>
    </item>
    <item>
      <title>Consumer Perceptions of Wearable Technology Devices: Retrospective Review and Analysis</title>
      <link>https://escholarship.org/uc/item/8kd6k1sr</link>
      <description>BACKGROUND: Individuals of all ages are becoming more health conscious, and wearable technology devices (eg, Fitbit and Apple Watch) are becoming increasingly popular in encouraging healthy lifestyles.
OBJECTIVE: The aim of this paper was to explore how consumers use wearable devices.
METHODS: A retrospective review was done on the top-rated verified purchase reviews of the Fitbit One posted on Amazon.com between January 2014 and August 2018. Relevant themes were identified by qualitatively analyzing open-ended reviews.
RESULTS: On retrieval, there were 9369 reviews with 7706 positive reviews and 1663 critical reviews. The top 100 positive and top 100 critical comments were subsequently analyzed. Four major themes were identified: sleep hygiene ("charts when you actually fall asleep, when you wake up during the night, when you're restless--and gives you a cumulative time of "actual sleep" as well as weekly averages."), motivation ("25 lbs lost after 8 months - best motivator ever!"),...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8kd6k1sr</guid>
      <pubDate>Fri, 17 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Chong, Kimberly PL</name>
      </author>
      <author>
        <name>Guo, Julia Z</name>
      </author>
      <author>
        <name>Deng, Xiaomeng</name>
        <uri>https://orcid.org/0000-0002-7095-1560</uri>
      </author>
      <author>
        <name>Woo, Benjamin KP</name>
        <uri>https://orcid.org/0000-0002-0127-4850</uri>
      </author>
    </item>
    <item>
      <title>Unmet social needs and colorectal cancer testing at 45-49 since the 2021 USPSTF recommendation</title>
      <link>https://escholarship.org/uc/item/5zh3c0fx</link>
      <description>BACKGROUND: In 2021, the United States Preventive Services Task Force (USPSTF) lowered the recommended starting age for colorectal cancer (CRC) screening from 50 to 45 for average-risk individuals. However, screening uptake among younger adults has been slow, and little is known about how social factors influence screening behaviors in this early-midlife cohort. This study examined associations between unmet social needs and CRC testing and modality among adults aged 45-49 following the updated USPSTF recommendation.
METHODS: This cross-sectional analysis of 2022 Behavioral Risk Factor Surveillance System data included adults aged 45-49 years. Outcomes included any CRC testing since the USPSTF recommendation update and initial modality (stool-based test vs colonoscopy) among tested individuals. Primary predictors included past-year housing, transportation, or food insecurity and total number of unmet social needs. Weighted binary logistic regression models were adjusted for sociodemographic...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5zh3c0fx</guid>
      <pubDate>Thu, 16 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Chen, Katherine L</name>
        <uri>https://orcid.org/0000-0002-4122-2916</uri>
      </author>
      <author>
        <name>Mangione, Carol M</name>
        <uri>https://orcid.org/0000-0002-9475-2275</uri>
      </author>
      <author>
        <name>Shih, Ya-Chen Tina</name>
        <uri>https://orcid.org/0000-0001-7290-3864</uri>
      </author>
    </item>
    <item>
      <title>RhoGEF Ect2 supports RhoA activity at cell–cell junctions through desmoplakin</title>
      <link>https://escholarship.org/uc/item/3c49s293</link>
      <description>Desmoplakin (DP) is an essential component of the desmosomal adhesion complex, tethering intermediate filaments to sites of intercellular adhesion to confer mechanical integrity to tissues. As a frequent target for mutation in cardiocutaneous syndromes that vary widely in phenotype, DP's roles as a signaling hub are rapidly emerging. Here, we identify the RhoGEF Ect2 as a previously unappreciated component of intercellular junctions in close association with DP. DP promotes the localization of Ect2 to keratinocyte desmosomes and cardiac intercalated discs, where it maintains active RhoA (Rho-GTP) at the membrane. We demonstrate that Ect2 activity is regulated by PKC in a DP-dependent manner in cardiac myocytes. Finally, a truncated form of DP expressed in patients with Carvajal syndrome associated with severe cardiocutaneous defects is impaired in its ability to bind and localize Ect2 to cell junctions in cardiomyocytes and patient keratinocytes. Our findings delineate an important...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3c49s293</guid>
      <pubDate>Thu, 16 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Zarkoob, Hoda</name>
      </author>
      <author>
        <name>Kam, Chen Y</name>
      </author>
      <author>
        <name>Koetsier, Jennifer L</name>
      </author>
      <author>
        <name>McCarthy, Erin</name>
      </author>
      <author>
        <name>Jaiganesh, Avinash</name>
      </author>
      <author>
        <name>Kelsell, David P</name>
      </author>
      <author>
        <name>Sheikh, Farah</name>
      </author>
      <author>
        <name>Godsel, Lisa M</name>
      </author>
      <author>
        <name>Green, Kathleen J</name>
      </author>
    </item>
    <item>
      <title>Skin capillary endothelial cells form a network of spatiotemporally conserved Ca2+ activity</title>
      <link>https://escholarship.org/uc/item/1jk574s5</link>
      <description>Ca&lt;sup&gt;2+&lt;/sup&gt; signaling and its regulation are important for endothelial cell (EC) function and signaling. Yet, the spatiotemporal organization of Ca&lt;sup&gt;2+&lt;/sup&gt; activity and its regulation across a vascular plexus is poorly understood in an in vivo mammalian context. To overcome this gap in knowledge, we developed an intravital imaging approach to resolve Ca&lt;sup&gt;2+&lt;/sup&gt; activity with single-cell resolution in skin vasculature of adult mice via multiphoton microscopy. Here, we tracked thousands of Ca&lt;sup&gt;2+&lt;/sup&gt; events in the skin capillary plexus during homeostasis and observed signaling heterogeneity between ECs, with just over half displaying Ca&lt;sup&gt;2+&lt;/sup&gt; activity at any given time. Longitudinal tracking of the same mice revealed that the same capillary ECs maintain Ca&lt;sup&gt;2+&lt;/sup&gt; activity over days to weeks. Interestingly, activity dynamics, such as frequency and event duration, are not conserved at a single-cell level but are maintained at an EC population level....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1jk574s5</guid>
      <pubDate>Thu, 16 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Swaminathan, Anush</name>
      </author>
      <author>
        <name>Gonzalez, David G</name>
      </author>
      <author>
        <name>Matte-Martone, Catherine</name>
      </author>
      <author>
        <name>Xu, Fei</name>
      </author>
      <author>
        <name>Simpson, Deandra</name>
      </author>
      <author>
        <name>Moore, Jessica L</name>
      </author>
      <author>
        <name>Lin, Zhongqi</name>
      </author>
      <author>
        <name>Rana, Ushnish</name>
      </author>
      <author>
        <name>Monedero-Alonso, David</name>
      </author>
      <author>
        <name>Mack, Julia J</name>
        <uri>https://orcid.org/0000-0002-9239-8436</uri>
      </author>
      <author>
        <name>Kam, Chen Yuan</name>
      </author>
      <author>
        <name>Greco, Valentina</name>
      </author>
    </item>
    <item>
      <title>Maternal residential proximity to oil and gas development in California and the risk of childhood cancer</title>
      <link>https://escholarship.org/uc/item/8jx6n74g</link>
      <description>This study investigates maternal residential proximity to oil and gas development (OGD) in pregnancy and the risk of multiple childhood cancers in California. Cases (N&amp;nbsp;=&amp;nbsp;9487) were identified from California Cancer Registry and controls (N&amp;nbsp;=&amp;nbsp;183834) were randomly selected from the California Birth Registry (20:1 frequency-matched by birth year: 1998-2016), restricting both to births within 10&amp;nbsp;km of OGD. Exposure was defined as residing within 1&amp;nbsp;km or 3&amp;nbsp;km of any well at birth; 'low' and 'high' exposures were defined by the median well count within each distance. Unconditional logistic regression models estimated cancer risks comparing each exposed group to the unexposed (residing 3-10&amp;nbsp;km from any well). The risks of several cancers among children of mothers exposed to any well increased: medulloblastoma (within 3&amp;nbsp;km: adjusted Odds Ratio (aOR): 1.40; 95% confidence interval (CI): 1.08, 1.82; low, aOR&amp;nbsp;=&amp;nbsp;1.27; 95% CI&amp;nbsp;=&amp;nbsp;0.93,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8jx6n74g</guid>
      <pubDate>Mon, 13 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Chen, Yixin</name>
      </author>
      <author>
        <name>Cushing, Lara J</name>
        <uri>https://orcid.org/0000-0003-0640-6450</uri>
      </author>
      <author>
        <name>Li, Shiwen</name>
      </author>
      <author>
        <name>Meng, Qi</name>
      </author>
      <author>
        <name>Cockburn, Myles</name>
      </author>
      <author>
        <name>Zhang, Zuo-feng</name>
        <uri>https://orcid.org/0000-0002-4669-3995</uri>
      </author>
      <author>
        <name>Ritz, Beate R</name>
      </author>
      <author>
        <name>Heck, Julia E</name>
        <uri>https://orcid.org/0000-0001-8713-8413</uri>
      </author>
    </item>
    <item>
      <title>Long COVID sequelae in heart transplant recipients</title>
      <link>https://escholarship.org/uc/item/7nb1c0t0</link>
      <description>Post acute sequelae of SARS-CoV-2 infection (also known as Long COVID) have been defined as symptoms that persist after 3 months from initial acute episode of COVID-19. While the pathophysiology and mechanisms that cause Long COVID are hypothesized as secondary to persistent inflammation and immune dysregulation, the burden of this disease remains difficult to estimate due to varied symptomatology. Solid-organ transplant recipients in particular remain a vulnerable population that has been disproportionately affected by the COVID-19 pandemic, and the impact of Long COVID among orthotopic heart transplant recipients (OHTRs)-a patient population on chronic immunosuppressive therapy-remains incompletely characterized. We sought to evaluate patient-reported Long COVID symptoms between OHTRs compared to patients with baseline cardiomyopathy. We conducted a prospective survey-based study of adult OHTRs and cardiomyopathy control patients with documented SARS-CoV-2 infection. Participants...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7nb1c0t0</guid>
      <pubDate>Thu, 2 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Lees, Christopher R</name>
      </author>
      <author>
        <name>Morad, Tyler</name>
      </author>
      <author>
        <name>Webb, Martine</name>
      </author>
      <author>
        <name>Sim, Myung S</name>
      </author>
      <author>
        <name>Hsu, Jeffrey J</name>
        <uri>https://orcid.org/0000-0002-9971-5916</uri>
      </author>
    </item>
    <item>
      <title>A Hierarchical and Multiscale Framework for Characterizing Mouse Sleep-Wake Dynamics from 14-Day Continuous EEG: Validation of Age- and Sex-Dependent Remodeling.</title>
      <link>https://escholarship.org/uc/item/70b1053q</link>
      <description>Aging disrupts sleep, but how these changes are structured across circadian time, vigilance states, and sex remains poorly understood, because most prior studies used single-sex cohorts and few days of recordings. We continuously recorded 14 days of EEG/EMG in 24 C57BL/6J mice using a balanced 2 × 2 design (young vs. old; male vs. female; &lt;i&gt;n&lt;/i&gt; = 6/group). A comprehensive multiscale analysis of the extended dataset enabled detailed reconstruction of 24 h sleep-wake architecture, better characterization of natural day-to-day variability including across multiple estrous cycles, and detection of rare bouts and transition events. Across seven levels of analysis, from circadian profiles to EEG spectral parameterization, the strongest aging effect was a dark-phase-specific 17-18% loss of theta-dominant active wake (TDW) in both sexes, with reciprocal increases in quiet wake (nTDW) and NREM sleep. We also identified a recurring N-shaped structural motif at the dark-to-light transition,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/70b1053q</guid>
      <pubDate>Thu, 2 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Kostin, Andrey</name>
      </author>
      <author>
        <name>Saevskiy, Anton</name>
      </author>
      <author>
        <name>Alam, Md</name>
      </author>
      <author>
        <name>Jiang, Yiqun</name>
      </author>
      <author>
        <name>Suntsova, Natalia</name>
      </author>
      <author>
        <name>Alam, Md</name>
      </author>
    </item>
    <item>
      <title>Vision-language model-based semantic-guided imaging biomarker for lung nodule malignancy prediction</title>
      <link>https://escholarship.org/uc/item/0787w780</link>
      <description>OBJECTIVE: Machine learning models have utilized semantic features, deep features, or both to assess lung nodule malignancy. However, their reliance on manual annotation during inference, limited interpretability, and sensitivity to imaging variations hinder their application in real-world clinical settings. Thus, this research aims to integrate semantic features derived from radiologists' assessments of nodules, guiding the model to learn clinically relevant, robust, and explainable imaging features for predicting lung cancer.
METHODS: We obtained 938 low-dose CT scans from the National Lung Screening Trial (NLST) with 1,261 nodules and semantic features. Additionally, the Lung Image Database Consortium dataset contains 1,018 CT scans, with 2,625 lesions annotated for nodule characteristics. Three external datasets were obtained from UCLA Health, the LUNGx Challenge, and the Duke Lung Cancer Screening. For imaging input, we obtained 2D nodule slices in nine directions from 50×50×50mm...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0787w780</guid>
      <pubDate>Wed, 1 Jul 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Zhuang, Luoting</name>
      </author>
      <author>
        <name>Tabatabaei, Seyed Mohammad Hossein</name>
      </author>
      <author>
        <name>Salehi-Rad, Ramin</name>
      </author>
      <author>
        <name>Tran, Linh M</name>
      </author>
      <author>
        <name>Aberle, Denise R</name>
        <uri>https://orcid.org/0000-0002-8858-3401</uri>
      </author>
      <author>
        <name>Prosper, Ashley E</name>
      </author>
      <author>
        <name>Hsu, William</name>
      </author>
    </item>
    <item>
      <title>Monoclonal Immunotactoid Glomerulopathy Associated With Chronic Lymphocytic Leukemia: A Case Report.</title>
      <link>https://escholarship.org/uc/item/65p3x8z1</link>
      <description>Immunotactoid glomerulopathy (ITG) is exceedingly rare in clinical practice. A majority of cases are associated with an underlying hematological disorder and specifically chronic lymphocytic leukemia (CLL). The treatment consists of managing the underlying disease and supportive therapy. We present the case of an 80-year-old patient with a history of CLL who presented with proteinuria and acute kidney injury and eventually developed hematuria. His renal biopsy revealed monoclonal ITG. He began a course of chemotherapy for CLL and achieved remission with improved renal function.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/65p3x8z1</guid>
      <pubDate>Mon, 29 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Badiee, Gholamreza</name>
      </author>
      <author>
        <name>Kalantary, Atefeh</name>
      </author>
      <author>
        <name>Shafiei, Sina</name>
      </author>
      <author>
        <name>Hou, Jean</name>
      </author>
      <author>
        <name>Lazarus, Michael</name>
      </author>
    </item>
    <item>
      <title>Campylobacter jejuni Enteritis Mimicking Mechanical Small Bowel Obstruction.</title>
      <link>https://escholarship.org/uc/item/4mb960g3</link>
      <description>In this case, we present an 84-year-old&amp;nbsp;patient admitted for small bowel obstruction (SBO) with radiographic evidence of a clear transition point in the proximal small bowel on a computed tomography (CT) scan. Given his prior history of hemicolectomy, surgical adhesions were suspected as the likely cause. After several days of poor response to supportive treatment, he developed significant secretory diarrhea with stool samples positive for &lt;i&gt;Campylobacter jejuni.&lt;/i&gt; In rare cases,&amp;nbsp;&lt;i&gt;C. jejuni&lt;/i&gt; enteritis can mimic SBO. We suggest that his SBO initially resembled mechanical obstruction on imaging due to significant bacterial induced circumferential bowel thickening and edema as opposed to the usual pseudo-obstruction from bacterial activated pro-inflammatory mediators, which disrupt intestinal motility. His obstruction resolved with a course of azithromycin antibiotics and conservative measures.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4mb960g3</guid>
      <pubDate>Mon, 29 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Shafiei, Sina</name>
      </author>
      <author>
        <name>Kalantary, Atefeh</name>
      </author>
      <author>
        <name>Alghussein, Mohammad</name>
      </author>
      <author>
        <name>Badiee, Gholamreza</name>
      </author>
      <author>
        <name>Talebi, Amir</name>
      </author>
      <author>
        <name>Lazarus, Michael</name>
      </author>
    </item>
    <item>
      <title>The mental health and well-being effects of wildfire smoke: a scoping review.</title>
      <link>https://escholarship.org/uc/item/6kc0t338</link>
      <description>&lt;h4&gt;Background&lt;/h4&gt;Smoke from wildfires is a growing public health risk due to the enormous amount of smoke-related pollution that is produced and can travel thousands of kilometers from its source. While many studies have documented the physical health harms of wildfire smoke, less is known about the effects on mental health and well-being. Understanding the effects of wildfire smoke on mental health and well-being is crucial as the world enters a time in which wildfire smoke events become more frequent and severe. We conducted a scoping review of the existing information on wildfire smokes impact on mental health and well-being and developed a model for understanding the pathways in which wildfire smoke may contribute to mental health distress.&lt;h4&gt;Methods&lt;/h4&gt;We conducted searches using PubMed, Medline, Embase, Google, Scopus, and ProQuest for 1990-2022. These searches yielded 200 articles. Sixteen publications met inclusion criteria following screening and eligibility assessment....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6kc0t338</guid>
      <pubDate>Fri, 19 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Eisenman, David</name>
      </author>
      <author>
        <name>Galway, Lindsay</name>
      </author>
    </item>
    <item>
      <title>Use of Evidence-Based Type 2 Diabetes Preventive Therapies and Rates of Progression to Diabetes Among Veterans with Prediabetes by Race and Ethnicity, 2010–2019</title>
      <link>https://escholarship.org/uc/item/5cn008xt</link>
      <description>Use of Evidence-Based Type 2 Diabetes Preventive Therapies and Rates of Progression to Diabetes Among Veterans with Prediabetes by Race and Ethnicity, 2010–2019</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5cn008xt</guid>
      <pubDate>Thu, 18 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Ly, Dan P</name>
        <uri>https://orcid.org/0000-0001-5760-0208</uri>
      </author>
      <author>
        <name>Washington, Donna L</name>
      </author>
      <author>
        <name>Shekelle, Paul G</name>
      </author>
      <author>
        <name>Lee, Martin L</name>
      </author>
      <author>
        <name>Moin, Tannaz</name>
      </author>
    </item>
    <item>
      <title>End-of-Life Care Processes and Outcomes for Older Adults Treated by International Medical Graduates vs. US Medical Graduates</title>
      <link>https://escholarship.org/uc/item/4k12q8kt</link>
      <description>ImportanceInternational medical graduates (IMGs—physicians who graduated from a medical school outside the US) hold a significant role in the US healthcare system. Research suggests that clinicians’ attitudes towards end-of-life (EOL) care may vary across countries.ObjectiveTo compare EOL care processes and outcomes for older adults treated by IMGs vs. US medical graduates (USMGs).DesignCross-sectional study.ParticipantsA 20% random sample of Medicare fee-for-service beneficiaries aged 66 years or older who died in 2016–2019.Main MeasuresSeven EOL care-related measures: (i) palliative care counseling or hospice enrollment in the last 180 days of life; (ii) emergency department visits, (iii) hospital admissions, (iv) intensive care unit admissions, (v) use of mechanical ventilation or cardiopulmonary resuscitation, or (vi) feeding tube placement in the last 30 days of life; and (vii) death in an acute care hospital. We adjusted for beneficiary- and physician-level confounders;...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4k12q8kt</guid>
      <pubDate>Thu, 18 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Kaneshiro, Gillian S</name>
      </author>
      <author>
        <name>Reuben, David B</name>
      </author>
      <author>
        <name>Zingmond, David S</name>
      </author>
      <author>
        <name>Walling, Anne M</name>
      </author>
      <author>
        <name>Jena, Anupam B</name>
      </author>
      <author>
        <name>Wenger, Neil S</name>
      </author>
      <author>
        <name>Damberg, Cheryl L</name>
      </author>
      <author>
        <name>Xu, Haiyong</name>
      </author>
      <author>
        <name>Gross, Nate</name>
      </author>
      <author>
        <name>Gotanda, Hiroshi</name>
      </author>
      <author>
        <name>Tsugawa, Yusuke</name>
        <uri>https://orcid.org/0000-0002-1937-4833</uri>
      </author>
    </item>
    <item>
      <title>A diagnostically challenging case of pemphigus foliaceus without histologic evidence of acantholysis</title>
      <link>https://escholarship.org/uc/item/0rz5b8h9</link>
      <description>A 77-year-old woman presented with pruritic, scaly, erythematous papules and plaques on the face which then spread to involve the trunk. Over nearly two years, five skin biopsies were performed which overall suggested a subacute to chronic eczematous process without acantholysis or intraepidermal bullae. After two years of failed treatment, antibody testing via enzyme-linked immunosorbent assay demonstrated elevated anti-Desmoglein-1 IgG and normal anti-Desmoglein-3 IgG, and a skin biopsy with direct immunofluorescence revealed IgG and C3 in the intercellular space. A diagnosis of pemphigus foliaceus was made, and the patient was treated with rituximab with significant improvement. Here, we present a diagnostically challenging case of pemphigus foliaceus in which multiple biopsies failed to detect acantholysis or intraepidermal bullae – classic histological findings of this condition, thus highlighting the importance of immunologic testing in the workup of suspected autoimmune...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0rz5b8h9</guid>
      <pubDate>Thu, 18 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Liu, Jennifer Y</name>
      </author>
      <author>
        <name>Scumpia, Philip</name>
      </author>
      <author>
        <name>Ni, Catherine</name>
      </author>
      <author>
        <name>Yashar, Sharona</name>
      </author>
      <author>
        <name>Langevin, Kathy</name>
      </author>
      <author>
        <name>Kang, Yuna</name>
      </author>
      <author>
        <name>Vandiver, Amy</name>
      </author>
    </item>
    <item>
      <title>Dietary Therapies for Gastrointestinal Disorders.</title>
      <link>https://escholarship.org/uc/item/0374k2rp</link>
      <description>Alterations in gastrointestinal function (digestion, absorption, motility, secretion, and elimination) play important roles in the pathophysiology of many gastrointestinal disorders. Food also strongly influences gastrointestinal health and disease. Some foods act as antigens that trigger an enteric immune response, while others can serve as substrates with direct or indirect biological effects. Food can also be metabolized by gut microbes into bioactive molecules that alter physiology. This review discusses the current research evidence and the clinical use of food as medicine through dietary therapies for the management of various gastrointestinal conditions, including disorders of gut-brain interaction, eosinophilic esophagitis, celiac disease, inflammatory bowel disease, gastroparesis, and short bowel syndrome with intestinal failure.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0374k2rp</guid>
      <pubDate>Thu, 18 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Limketkai, Berkeley</name>
      </author>
      <author>
        <name>Shin, Andrea</name>
      </author>
      <author>
        <name>Manitius, Natalie</name>
      </author>
      <author>
        <name>Rau, Sameeha</name>
      </author>
      <author>
        <name>Smith, Janelle</name>
      </author>
      <author>
        <name>Shah, Neha</name>
      </author>
    </item>
    <item>
      <title>Pharmacist-Led Discharge Care to Reduce Postdischarge Health Care Utilization</title>
      <link>https://escholarship.org/uc/item/9rf7k2zk</link>
      <description>Importance: Pharmacist-led peridischarge transitions of care (TOC) interventions reduce adverse drug events after hospitalization. However, health care organizations do not usually see a financial incentive to fund these interventions.
Objective: To test whether pharmacist-led TOC interventions could drive reductions in health care resource utilization after hospital discharge.
Design, Setting, and Participants: This pragmatic randomized clinical trial was conducted in 2 urban teaching hospitals in the US. Participants were hospitalized adults aged 55 years or older taking 10 or more long-term prescribed medications or 3 or more high-risk medications (defined as anticoagulants, antiplatelet agents, or antihyperglycemics including insulin), enrolled between December 23, 2019, and December 30, 2022. Data were analyzed from January 2023 to June 2025.
Intervention: Pharmacist-led peridischarge and postdischarge medication management with patients and their care partners, including...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9rf7k2zk</guid>
      <pubDate>Wed, 17 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Pevnick, Joshua M</name>
        <uri>https://orcid.org/0000-0003-0621-1485</uri>
      </author>
      <author>
        <name>Kennelty, Korey</name>
      </author>
      <author>
        <name>Nguyen, An T</name>
      </author>
      <author>
        <name>Amer, Kallie</name>
      </author>
      <author>
        <name>Berdahl, Carl T</name>
      </author>
      <author>
        <name>Cook-Wiens, Galen</name>
      </author>
      <author>
        <name>Fanikos, John</name>
      </author>
      <author>
        <name>Fiskio, Julie</name>
      </author>
      <author>
        <name>Gotanda, Hiroshi</name>
      </author>
      <author>
        <name>Guan, James</name>
      </author>
      <author>
        <name>Henreid, Andrew J</name>
      </author>
      <author>
        <name>Keller, Michelle S</name>
        <uri>https://orcid.org/0000-0002-8157-7586</uri>
      </author>
      <author>
        <name>Ko, Eunji M</name>
      </author>
      <author>
        <name>Leang, Donna W</name>
      </author>
      <author>
        <name>Malkhasian, Yervant</name>
      </author>
      <author>
        <name>Matta, Lina</name>
      </author>
      <author>
        <name>Moriarty, Dylan</name>
      </author>
      <author>
        <name>Murry, Logan</name>
      </author>
      <author>
        <name>Muske, Annie</name>
      </author>
      <author>
        <name>Nuckols, Teryl K</name>
      </author>
      <author>
        <name>Oche, Onyeche</name>
      </author>
      <author>
        <name>Ortiz, Audrienne S</name>
      </author>
      <author>
        <name>Phung, Emily</name>
      </author>
      <author>
        <name>Qureshi, Nabeel</name>
      </author>
      <author>
        <name>Shane, Rita</name>
      </author>
      <author>
        <name>Wu, Shirley</name>
      </author>
      <author>
        <name>Schnipper, Jeffrey L</name>
      </author>
      <author>
        <name>Armbruster, Christine</name>
      </author>
      <author>
        <name>Conti, Nicole</name>
      </author>
      <author>
        <name>Corrado, Michael</name>
      </author>
      <author>
        <name>Llamas-Sandoval, Ruby</name>
      </author>
      <author>
        <name>Mai, Emily</name>
      </author>
      <author>
        <name>Migeed, Sarah</name>
      </author>
      <author>
        <name>Oneil, Kelsey</name>
      </author>
      <author>
        <name>Rosen, Olga</name>
      </author>
      <author>
        <name>Rosen, Sonja</name>
      </author>
      <author>
        <name>Smith, Madison</name>
      </author>
      <author>
        <name>Smith, William</name>
      </author>
      <author>
        <name>Thao, Lilly Kasha</name>
      </author>
      <author>
        <name>Wisniewski, Jesse</name>
      </author>
      <author>
        <name>Xiao, Yi Tian</name>
      </author>
      <author>
        <name>Chaitoff, Alexander</name>
      </author>
    </item>
    <item>
      <title>A Rare Case of Methamphetamine-Induced Diffuse Gastrointestinal Ischemia</title>
      <link>https://escholarship.org/uc/item/85749500</link>
      <description>Methamphetamine is a widely used substance known for cardiovascular and neurological complications; however, its gastrointestinal effects remain poorly understood. While rare, methamphetamine-induced gastrointestinal ischemia has high morbidity and mortality rates, with limited case reports in the literature. We present a case of a 48-year-old man with a history of gastroesophageal reflux disease, alcohol use disorder in remission, and previously documented methamphetamine use who presented with two weeks of episodic abdominal pain, nausea, and hematemesis. Significant laboratory and imaging findings included acute anemia, urine toxicology confirming the presence of amphetamines, and computed tomography imaging showing wall thickening in the distal esophagus and stomach. On endoscopy, he was found to have diffuse ulcerations in the distal esophagus and post-pyloric region with pathology indicative of methamphetamine-induced gastrointestinal ischemia.&amp;nbsp;This case highlights...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/85749500</guid>
      <pubDate>Wed, 17 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Johnsen, Nicole</name>
      </author>
      <author>
        <name>Chang, Andrew</name>
      </author>
      <author>
        <name>Chuang, Kelley</name>
      </author>
      <author>
        <name>Patel, Satya</name>
        <uri>https://orcid.org/0000-0002-1389-0829</uri>
      </author>
      <author>
        <name>Wu, Simon</name>
      </author>
    </item>
    <item>
      <title>American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum.</title>
      <link>https://escholarship.org/uc/item/0pw091c0</link>
      <description>&lt;h4&gt;Background&lt;/h4&gt;Thyroid disease in pregnancy, preconception, and postpartum is a common and clinically relevant problem. Since the publication of the American Thyroid Association (ATA) guidelines in 2017, substantial new clinical and scientific evidence has become available. The aim of these guidelines is to provide clinicians, patients, researchers, and policymakers with evidence-based recommendations on the care of women with thyroid disease before, during, and after pregnancy.&lt;h4&gt;Methods&lt;/h4&gt;The clinical questions addressed were informed by prior ATA guidelines, stakeholder feedback, a global needs assessment, and input from the multidisciplinary task force. Systematic literature searches were conducted with the support from a medical librarian and evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation framework. Recommendations were formulated based on the quality of evidence, balance of benefits and harms, patient values, feasibility, and...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/0pw091c0</guid>
      <pubDate>Wed, 17 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Korevaar, Tim IM</name>
        <uri>https://orcid.org/0000-0001-7961-8791</uri>
      </author>
      <author>
        <name>Leung, Angela M</name>
        <uri>https://orcid.org/0000-0001-8935-9332</uri>
      </author>
      <author>
        <name>Alexander, Erik K</name>
      </author>
      <author>
        <name>Bliddal, Sofie</name>
      </author>
      <author>
        <name>Boelaert, Kristien</name>
      </author>
      <author>
        <name>Brenta, Gabriela</name>
      </author>
      <author>
        <name>Chou, Roger</name>
      </author>
      <author>
        <name>Dhillon-Smith, Rima</name>
      </author>
      <author>
        <name>Dosiou, Chrysoula</name>
      </author>
      <author>
        <name>Eaton, Jennifer L</name>
      </author>
      <author>
        <name>Guan, Haixia</name>
      </author>
      <author>
        <name>Kilpatrick, Sarah J</name>
      </author>
      <author>
        <name>Lasserre, Bente J</name>
      </author>
      <author>
        <name>Lee, Sun Y</name>
      </author>
      <author>
        <name>Maraka, Spyridoula</name>
      </author>
      <author>
        <name>Meister, Kara D</name>
      </author>
      <author>
        <name>Morris-Wiseman, Lilah F</name>
      </author>
      <author>
        <name>Nguyen, Caroline T</name>
      </author>
      <author>
        <name>Pearce, Elizabeth N</name>
      </author>
      <author>
        <name>Shan, Zhongyan</name>
      </author>
    </item>
    <item>
      <title>Evaluating the Acceptability of Using Virtual Reality to Promote Physical Activity Among Latino, Latina, and Latine Adults With Cardiometabolic Risk Factors and Obesity in Underresourced Settings: Protocol for a Qualitative Focus Group Study</title>
      <link>https://escholarship.org/uc/item/3jv7n9t3</link>
      <description>Background: Obesity represents a significant public health challenge in the United States, particularly among Latino, Latina, and Latine communities and those in underresourced settings. Virtual reality (VR) is a new and innovative technology that can promote physical activity and has the potential to overcome some structural barriers. However, there are few studies that explore the acceptability of using this new technology among high-risk groups in underresourced settings.
Objective: We outline a community-informed protocol for conducting focus groups with Latino, Latina, and Latine adults who have cardiometabolic risk factors and obesity residing in underresourced communities. The focus groups will assess the acceptability of a culturally aligned VR program to promote physical activity.
Methods: Using a community-engaged approach informed by community health workers and a community advisory board, we delivered an immersive VR dance experience to Latino, Latina, and Latine adult...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3jv7n9t3</guid>
      <pubDate>Wed, 10 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Acosta, Desiree R</name>
      </author>
      <author>
        <name>Aguilar-Hernandez, Leslie</name>
      </author>
      <author>
        <name>Perez, Gael</name>
      </author>
      <author>
        <name>Guzman-Ruiz, Iris Y</name>
      </author>
      <author>
        <name>Castellon, Josyel M</name>
      </author>
      <author>
        <name>Cruz, Jailene</name>
      </author>
      <author>
        <name>Gutierrez, Liana</name>
      </author>
      <author>
        <name>Monteon-Garcia, Paulina</name>
      </author>
      <author>
        <name>Torres, Vanessa N</name>
      </author>
      <author>
        <name>Duru, O Kenrik</name>
      </author>
      <author>
        <name>Castellon-Lopez, Yelba</name>
      </author>
    </item>
    <item>
      <title>Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study.</title>
      <link>https://escholarship.org/uc/item/4cd0z05s</link>
      <description>&lt;h4&gt;Introduction&lt;/h4&gt;The KEYNOTE-522 clinical trial demonstrated that the addition of pembrolizumab to 8 cycles of neoadjuvant chemotherapy (NAC) improves pathologic complete response (pCR) rates and overall survival in early-stage triple-negative breast cancer (TNBC). However, predictors of response and the benefit of alternative NAC backbones with immunotherapy are not known. This multi-institutional study evaluates clinical factors and treatment variables associated with pCR following NAC plus pembrolizumab in a diverse, real-world cohort.&lt;h4&gt;Methods&lt;/h4&gt;This multi-institution retrospective study analyzed patients with early-stage TNBC diagnosed between July 1, 2021, and December 31, 2023, across three hospital systems. Eligible patients received at least one cycle of NAC and pembrolizumab. Predictors of pCR were assessed using logistic regression.&lt;h4&gt;Results&lt;/h4&gt;Of the 374 patients included, the pCR rate was 61.2%. The cohort was racially and ethnically diverse, with 29.1%...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/4cd0z05s</guid>
      <pubDate>Fri, 5 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>LeVee, Alexis</name>
      </author>
      <author>
        <name>Santos, Bethania</name>
      </author>
      <author>
        <name>Wong, Megan</name>
      </author>
      <author>
        <name>Ruel, Nora</name>
      </author>
      <author>
        <name>Schmolze, Daniel</name>
      </author>
      <author>
        <name>Kang, Irene</name>
      </author>
      <author>
        <name>Tsai, Karen</name>
      </author>
      <author>
        <name>Mortimer, Joanne</name>
      </author>
      <author>
        <name>McArthur, Heather</name>
      </author>
    </item>
    <item>
      <title>Translating a Preclinical Hydrogel Platform into a Human Therapeutic for Delivering Targeted Low-Dose Anti-CTLA-4</title>
      <link>https://escholarship.org/uc/item/759127hw</link>
      <description>Systemic administration of antibodies that target immune checkpoint inhibitor pathways is a highly effective approach to cancer immunotherapy, but systemic toxicity can limit clinical utility. In preclinical testing, a peri-tumor injection of a low dose of hydrogel-encapsulated cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody was shown to selectively activate T cells in tumor-draining lymph nodes, induce tumor infiltration by cytotoxic T cells, and result in tumor regression, protective immunity, and long-term survival. In contrast to systemic therapy, there was limited systemic exposure or risk for autoimmune toxicity. The current study focuses on translating this platform into a biocompatible human therapeutic. The hydrogel matrix was reformulated using a low-molecular-weight hyaluronic acid. A recombinant human hyaluronidase (rHuPH20) was incorporated to promote lymph node targeting and self-resorbing features. Formulations were optimized to operate at neutral...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/759127hw</guid>
      <pubDate>Thu, 4 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Harui, Airi</name>
      </author>
      <author>
        <name>Roth, Michael D</name>
        <uri>https://orcid.org/0000-0003-2194-6578</uri>
      </author>
    </item>
    <item>
      <title>Elevated AD biomarkers do not explain cognitive performance in a community‐recruited clinical trial cohort</title>
      <link>https://escholarship.org/uc/item/6pr3b9x9</link>
      <description>INTRODUCTION: To examine the generalizability of Alzheimer's disease (AD) biomarker models in real-world older adults, we examined AD biomarker relationships with cognition in two multicenter cohorts that differ with respect to recruitment approach and health risk factors but were matched on a variety of characteristics.
METHODS: We compared harmonized health and demographic data, AD and cerebrovascular biomarkers, and cognitive performance in the community-recruited U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) Imaging substudy and a matched sample from the Alzheimer's Disease Neuroimaging Initiative (ADNI) which recruited primarily from academic specialty clinics.
RESULTS: Elevated β-amyloid (Aβ) and tau were associated with cognitive performance in ADNI but not U.S. POINTER. Findings were consistent across different cohort matching schemes, and were not explained by discrepancies in vascular risk.
DISCUSSION: The role of Aβ...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6pr3b9x9</guid>
      <pubDate>Thu, 4 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Landau, Susan M</name>
      </author>
      <author>
        <name>Liu, Peiwei</name>
      </author>
      <author>
        <name>Harrison, Theresa M</name>
      </author>
      <author>
        <name>Taggett, Jacinda</name>
      </author>
      <author>
        <name>Ward, Tyler J</name>
      </author>
      <author>
        <name>Murphy, Alice</name>
      </author>
      <author>
        <name>Lockhart, Samuel N</name>
      </author>
      <author>
        <name>Lovato, Laura C</name>
      </author>
      <author>
        <name>Koeppe, Robert</name>
      </author>
      <author>
        <name>Farias, Sarah Tomaszewski</name>
      </author>
      <author>
        <name>Papp, Kathryn V</name>
      </author>
      <author>
        <name>Snyder, Heather M</name>
      </author>
      <author>
        <name>Harvey, Danielle J</name>
        <uri>https://orcid.org/0000-0002-5367-0951</uri>
      </author>
      <author>
        <name>Espeland, Mark</name>
      </author>
      <author>
        <name>Maillard, Pauline</name>
      </author>
      <author>
        <name>DeCarli, Charles</name>
      </author>
      <author>
        <name>Vemuri, Prashanthi</name>
      </author>
      <author>
        <name>Weiner, Michael</name>
        <uri>https://orcid.org/0000-0002-0877-4583</uri>
      </author>
      <author>
        <name>Baker, Laura D</name>
      </author>
      <author>
        <name>Jagust, William J</name>
      </author>
      <author>
        <name>Weiner, Michael W</name>
      </author>
      <author>
        <name>Trojanowski, John Q</name>
      </author>
      <author>
        <name>Shaw, Leslie</name>
      </author>
      <author>
        <name>Beckett, Laurel</name>
      </author>
      <author>
        <name>Aisen, Paul</name>
      </author>
      <author>
        <name>Petersen, Ronald</name>
      </author>
      <author>
        <name>Saykin, Andrew J</name>
      </author>
      <author>
        <name>Toga, Arthur W</name>
      </author>
      <author>
        <name>Jack, Clifford</name>
      </author>
      <author>
        <name>Morris, John C</name>
      </author>
      <author>
        <name>Jagust, William</name>
      </author>
      <author>
        <name>Landau, Susan M</name>
      </author>
      <author>
        <name>Baker, Laura D</name>
      </author>
      <author>
        <name>Espeland, Mark A</name>
      </author>
      <author>
        <name>Vemuri, Prashanthi</name>
      </author>
      <author>
        <name>DeCarli, Charles</name>
        <uri>https://orcid.org/0000-0003-1914-2693</uri>
      </author>
      <author>
        <name>Harrison, Theresa M</name>
      </author>
      <author>
        <name>Koeppe, Robert A</name>
      </author>
      <author>
        <name>Jagust, William J</name>
      </author>
      <author>
        <name>Maillard, Pauline</name>
        <uri>https://orcid.org/0000-0003-3516-6345</uri>
      </author>
      <author>
        <name>Jung, Youngkyoo</name>
        <uri>https://orcid.org/0000-0002-7236-8897</uri>
      </author>
      <author>
        <name>Lovato, Laura</name>
      </author>
      <author>
        <name>Harvey, Danielle J</name>
      </author>
      <author>
        <name>Toga, Arthur W</name>
      </author>
      <author>
        <name>Zamora, Ezequiel</name>
      </author>
      <author>
        <name>Cleveland, Jo</name>
      </author>
      <author>
        <name>DeCarli, Charles</name>
      </author>
      <author>
        <name>Whitmer, Rachel</name>
      </author>
      <author>
        <name>Aggarwal, Neelum</name>
      </author>
      <author>
        <name>Tangney, Christy</name>
      </author>
      <author>
        <name>Gitelman, Darren</name>
      </author>
      <author>
        <name>Masdeu, Joseph</name>
      </author>
      <author>
        <name>Pavlik, Valory</name>
      </author>
      <author>
        <name>Yu, Melissa</name>
      </author>
      <author>
        <name>Oh, Hwamee</name>
      </author>
      <author>
        <name>Huey, Edward</name>
      </author>
      <author>
        <name>Salloway, Steve</name>
      </author>
      <author>
        <name>Wing, Rena</name>
      </author>
    </item>
    <item>
      <title>Clinical Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Among Older Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.</title>
      <link>https://escholarship.org/uc/item/9q90z5xt</link>
      <description>BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors (SGLT2i) reduce cardiovascular events in randomized controlled trials of patients with heart failure with reduced ejection fraction (HFrEF), but these trials enrolled outpatient, relatively younger patients (median age 66-67). The effectiveness of SGLT2i in older patients hospitalized for HFrEF in routine US clinical practice is not well studied.
METHODS: This study included Medicare beneficiaries aged ≥65 years hospitalized for HFrEF and eligible for SGLT2i in Get with the Guidelines-Heart Failure between July 1, 2021 and June 30, 2023. Primary outcomes were 30-day and 1-year all-cause mortality, all-cause readmission, and HF readmission. Association between SGLT2i and outcomes was assessed with Cox regression and overlap weighting using propensity score estimates.
RESULTS: A total of 8847 patients were eligible for but not prescribed SGLT2i at hospital admission (Median age 77; 40% women; median left ventricular EF...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9q90z5xt</guid>
      <pubDate>Wed, 3 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Brownell, Nicholas</name>
        <uri>https://orcid.org/0000-0001-8156-0808</uri>
      </author>
      <author>
        <name>Solomon, Nicole</name>
      </author>
      <author>
        <name>Greene, Stephen J</name>
      </author>
      <author>
        <name>Chiswell, Karen</name>
      </author>
      <author>
        <name>Vaduganathan, Muthiah</name>
      </author>
      <author>
        <name>Yancy, Clyde</name>
      </author>
      <author>
        <name>Hsue, Priscilla</name>
      </author>
      <author>
        <name>Ziaeian, Boback</name>
        <uri>https://orcid.org/0000-0001-9787-3649</uri>
      </author>
      <author>
        <name>Fonarow, Gregg C</name>
        <uri>https://orcid.org/0000-0002-3192-8093</uri>
      </author>
    </item>
    <item>
      <title>Disseminated multidrug-resistant Salmonella enterica serovar Dublin infection associated with plasmid-borne CMY-2 gene in a patient with travel to a farm in Mexico</title>
      <link>https://escholarship.org/uc/item/8tt9674t</link>
      <description>Disseminated Salmonella enterica infections represent a severe form of non-typhoidal salmonellosis increasingly complicated by antimicrobial resistance. We describe a case of disseminated non-typhoidal Salmonella in a man presenting with septic shock concerning for a thoracoabdominal endovascular graft infection with involvement of the urinary and respiratory tracts and thoracic skeleton. Hybrid whole-genome sequencing identified Salmonella enterica serovar Dublin and two significant plasmids, an IncC multidrug resistance plasmid harboring blaCMY−2, blaTEM−206, tet(A), and sul2 and an IncFII(S)/IncX1 virulence plasmid containing a spvA-D/spvR operon associated with systemic infection. This case highlights a potential food-borne or zoonotic acquisition of invasive, plasmid-mediated AmpC-producing Salmonella Dublin.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8tt9674t</guid>
      <pubDate>Wed, 3 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Collins, Mackenzie E</name>
      </author>
      <author>
        <name>Fung, Lilian</name>
      </author>
      <author>
        <name>Brewer, Timothy F</name>
      </author>
      <author>
        <name>Yang, Shangxin</name>
        <uri>https://orcid.org/0000-0001-9991-1178</uri>
      </author>
    </item>
    <item>
      <title>Representation of People Experiencing Homelessness in U.S. Medical Licensing Exam Question Banks</title>
      <link>https://escholarship.org/uc/item/6th0954t</link>
      <description>Representation of People Experiencing Homelessness in U.S. Medical Licensing Exam Question Banks</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6th0954t</guid>
      <pubDate>Wed, 3 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Johnson, Shawn</name>
      </author>
      <author>
        <name>Doran, Kelly M</name>
      </author>
      <author>
        <name>Grant, Matthew</name>
      </author>
      <author>
        <name>Nguemeni Tiako, Max Jordan</name>
      </author>
    </item>
    <item>
      <title>A primer on quality improvement</title>
      <link>https://escholarship.org/uc/item/60p950tf</link>
      <description>This Last Page provides a guide that can help trainees and faculty navigate the quality improvement process, introduce them to available resources, and become valuable agents of change.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/60p950tf</guid>
      <pubDate>Wed, 3 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Patel, Satya</name>
        <uri>https://orcid.org/0000-0002-1389-0829</uri>
      </author>
      <author>
        <name>Moolchandani, Priyanka</name>
      </author>
      <author>
        <name>Larsen, Tyler</name>
      </author>
      <author>
        <name>Moriates, Christopher</name>
      </author>
    </item>
    <item>
      <title>Medicaid Coverage Restrictions and On-Label Buprenorphine Prescribing for Chronic Pain</title>
      <link>https://escholarship.org/uc/item/5586m41k</link>
      <description>Medicaid Coverage Restrictions and On-Label Buprenorphine Prescribing for Chronic Pain</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5586m41k</guid>
      <pubDate>Wed, 3 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Nguemeni Tiako, Max Jordan</name>
        <uri>https://orcid.org/0000-0002-5468-8926</uri>
      </author>
      <author>
        <name>Abrams, Matthew Phillip</name>
      </author>
      <author>
        <name>Pinto Taylor, Emily</name>
      </author>
    </item>
    <item>
      <title>Postpartum Persistent Opioid Use After Opioid Exposure for Childbirth</title>
      <link>https://escholarship.org/uc/item/53j9t50w</link>
      <description>&lt;h4&gt;Objective&lt;/h4&gt;To assess the association between opioid exposure in the childbirth period and persistent postpartum opioid use and to evaluate whether there are differential associations based on specific medication exposure.&lt;h4&gt;Methods&lt;/h4&gt;Retrospective cohort study that used 2015-2021 Pennsylvania Medicaid claims of women aged 19-50 years with vaginal or cesarean delivery and Medicaid enrollment for at least 10 months during the postpartum year. Primary exposure was filled opioid prescription from 7 days before delivery to 8 weeks after delivery (childbirth period). The main outcome measure was persistent postpartum opioid use , defined as either a diagnosis of opioid use disorder or at least one filled opioid prescription in two or more calendar quarters from 8 weeks to 14 months postpartum. Multivariable logistic regression analyses included demographic information, mental health and behavioral comorbidities, obstetric trauma, and pre-existing pain conditions with subgroup...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/53j9t50w</guid>
      <pubDate>Wed, 3 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Matone, Meredith</name>
      </author>
      <author>
        <name>Nguemeni Tiako, Max Jordan</name>
      </author>
      <author>
        <name>Strane, Doug</name>
      </author>
      <author>
        <name>Luan, Xianqun</name>
      </author>
      <author>
        <name>Meisel, Zachary</name>
      </author>
    </item>
    <item>
      <title>Addressing Primary Care Needs in People Living With Sickle Cell Disease : A Narrative Review.</title>
      <link>https://escholarship.org/uc/item/3mf6p549</link>
      <description>Adults with sickle cell disease (SCD) are living longer due to advances in care but face a growing burden of chronic comorbid conditions that fall within the scope of primary care. However, primary care providers often lack structured guidance because literature on managing these conditions in the context of SCD is limited. This article outlines clinical approaches to hypertension, diabetes, obesity, chronic constipation, reproductive health, cognitive impairments, depression, and anxiety in people living with SCD. The authors highlight relevant epidemiology, screening recommendations, and treatment considerations that differ from those in the general population. Primary care providers play a crucial role in delivering comprehensive and preventive care to people living with SCD. Specific management of common chronic conditions in this population is necessary to reduce morbidity and improve quality of life.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3mf6p549</guid>
      <pubDate>Wed, 3 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Patel, Amie</name>
      </author>
      <author>
        <name>Wright, Charmaine</name>
      </author>
      <author>
        <name>Coyne, Francis</name>
      </author>
      <author>
        <name>Klein, Rachel J</name>
      </author>
      <author>
        <name>Nguemeni Tiako, Max Jordan</name>
      </author>
      <author>
        <name>Kuo, Alice A</name>
      </author>
      <author>
        <name>Cronin, Robert M</name>
      </author>
    </item>
    <item>
      <title>Oxysterol, Oxy210, Inhibits Hepatic Expression of Senescence-Associated and Pro-Fibrotic Genes in Humanized Hyperlipidemic Mice During Development of MASH and in Human Hepatocytes In Vitro</title>
      <link>https://escholarship.org/uc/item/2w24d5qc</link>
      <description>Background: Senescence, a state of permanent cell cycle arrest, is a complex cellular phenomenon closely affiliated with age-related diseases and pathological fibrosis. Cellular senescence is now recognized as a significant contributor to organ fibrosis, largely driven by transforming growth factor beta (TGF-β) signaling, such as in metabolic dysfunction-associated steatohepatitis (MASH), idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD), myocardial fibrosis that can lead to heart failure, cystic fibrosis, and fibrosis in pancreatic tumors to name a few. MASH is a progressive inflammatory and fibrotic liver condition that has reached pandemic proportions, now considered the largest non-viral contributor to the need for liver transplantation. Methods: We previously studied Oxy210, an antifibrotic and anti-inflammatory, orally bioavailable, oxysterol-based drug candidate for MASH, using APOE*3-Leiden.CETP mice, a humanized hyperlipidemic mouse model that closely...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2w24d5qc</guid>
      <pubDate>Wed, 3 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Wang, Feng</name>
      </author>
      <author>
        <name>Hui, Simon T</name>
        <uri>https://orcid.org/0000-0003-3540-3013</uri>
      </author>
      <author>
        <name>Stappenbeck, Frank</name>
      </author>
      <author>
        <name>Kaminska, Dorota</name>
      </author>
      <author>
        <name>Lusis, Aldons J</name>
        <uri>https://orcid.org/0000-0001-9013-0228</uri>
      </author>
      <author>
        <name>Parhami, Farhad</name>
      </author>
    </item>
    <item>
      <title>Cardiotoxicity prevention trials in the era of contemporary cancer therapies: a systematic review</title>
      <link>https://escholarship.org/uc/item/9vv500t9</link>
      <description>BackgroundCardiovascular toxicity is an increasingly important limitation of effective contemporary cancer therapies. Yet, the extent to which trials focus on preventing cardiotoxic events in patients receiving contemporary therapies is unknown.MethodsLeveraging PubMed, CENTRAL, clinicaltrials.gov, and publicly available reviews to identify all randomized controlled trials (RCTs) testing interventions for prevention or management of cardiotoxicity in cancer patients through 2024, we assessed the proportion of cardiotoxicity prevention trials that studied contemporary cancer therapies (biologic, targeted, or immune-based therapies). We included RCTs of interventional therapies/strategies against cardiotoxicity during cancer treatment. Data on trial baseline characteristics, design, funding, and reporting were extracted. Regression models were used to define trial and population factors associated with drug selection, reporting bias, and subsequent translation into guidelines.ResultsOverall,...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9vv500t9</guid>
      <pubDate>Tue, 2 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Munir, Malak</name>
      </author>
      <author>
        <name>Sayed, Ahmed</name>
      </author>
      <author>
        <name>Ghazi, Sanam</name>
      </author>
      <author>
        <name>Yang, Eric H</name>
        <uri>https://orcid.org/0000-0003-4889-7454</uri>
      </author>
      <author>
        <name>Guha, Avirup</name>
      </author>
      <author>
        <name>Epperla, Narendranath</name>
      </author>
      <author>
        <name>Addison, Daniel</name>
      </author>
    </item>
    <item>
      <title>Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies</title>
      <link>https://escholarship.org/uc/item/7tc829rs</link>
      <description>Sex differences influence cancer incidence, treatment response, and susceptibility to cardiovascular toxicity. Males exhibit higher rates and poorer outcomes in most non-sex-specific cancers, while females more frequently experience treatment-related adverse events, including cancer therapy-related cardiac dysfunction. Biological factors such as hormonal status, genetic polymorphisms, immune responses, and pharmacokinetics contribute to these disparities. In cardio-oncology, women—particularly premenopausal or with specific genotypes—may be at increased risk for cardiotoxicity after treatment with anthracyclines, immune checkpoint inhibitors or radiotherapy. Clonal hematopoiesis and certain germline genetic variants such as single nucleotide polymorphisms (e.g., RARG rs2229774, HAS3 rs2232228) are emerging as potential sex-informed biomarkers for predicting cardiotoxicity risk. Despite growing evidence, sex remains insufficiently integrated into clinical trials and guideline development...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/7tc829rs</guid>
      <pubDate>Tue, 2 Jun 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Keramida, Kalliopi</name>
        <uri>https://orcid.org/0000-0002-9533-6951</uri>
      </author>
      <author>
        <name>Aznar, Marianne C</name>
      </author>
      <author>
        <name>Bergler-Klein, Jutta</name>
        <uri>https://orcid.org/0000-0003-2591-1380</uri>
      </author>
      <author>
        <name>Boriani, Giuseppe</name>
        <uri>https://orcid.org/0000-0002-9820-4815</uri>
      </author>
      <author>
        <name>Cardinale, Daniela</name>
        <uri>https://orcid.org/0000-0002-4038-8033</uri>
      </author>
      <author>
        <name>Dent, Susan</name>
      </author>
      <author>
        <name>Drakaki, Alexandra</name>
        <uri>https://orcid.org/0000-0001-8865-3548</uri>
      </author>
      <author>
        <name>Fuster, Jose J</name>
        <uri>https://orcid.org/0000-0002-5970-629X</uri>
      </author>
      <author>
        <name>Mamas, Mamas A</name>
      </author>
      <author>
        <name>Okwuosa, Tochi</name>
      </author>
      <author>
        <name>Scarfo, Lydia</name>
      </author>
      <author>
        <name>Van Der Meer, Peter</name>
      </author>
      <author>
        <name>Yang, Eric H</name>
        <uri>https://orcid.org/0000-0003-4889-7454</uri>
      </author>
      <author>
        <name>Lopez-Fernandez, Teresa</name>
      </author>
    </item>
    <item>
      <title>Estimating Lung Cancer Screening Eligibility in the Veterans Health Administration Using Patient-Reported Smoking Histories</title>
      <link>https://escholarship.org/uc/item/6j24b9sz</link>
      <description>BackgroundThe Veterans Health Administration (VHA) serves a population at increased risk for lung cancer, but lung cancer screening (LCS) rates historically have been low. Understanding the size and characteristics of the screening-eligible population can provide insights for improving screening rates. Many screening eligibility recommendations rely on smoking intensity quantified in “pack-years,” which historically has been challenging to obtain at scale from the medical record. Recent introduction of structured smoking data as part of VHA LCS efforts now allows for more robust identification and estimation of the screening-eligible population using a large body of patient-reported smoking histories.ObjectiveTo estimate the magnitude and characteristics of the LCS-eligible population served by the VHA nationwide based on United States Preventive Services Task Force (USPSTF) and American Cancer Society (ACS) recommendations.DesignWe performed a retrospective, cross-sectional analysis...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/6j24b9sz</guid>
      <pubDate>Fri, 22 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Benjamin, Lawrence N</name>
      </author>
      <author>
        <name>Motwani, Yash</name>
      </author>
      <author>
        <name>Mangione, Carol M</name>
        <uri>https://orcid.org/0000-0002-9475-2275</uri>
      </author>
      <author>
        <name>Chen, Lillian</name>
      </author>
      <author>
        <name>Yuan, Anita</name>
      </author>
      <author>
        <name>Yano, Elizabeth M</name>
        <uri>https://orcid.org/0000-0002-9385-0025</uri>
      </author>
      <author>
        <name>Washington, Donna L</name>
      </author>
      <author>
        <name>Slatore, Christopher G</name>
      </author>
      <author>
        <name>Elashoff, David A</name>
      </author>
    </item>
    <item>
      <title>Assessing mpox knowledge and sexual behaviours within high-risk populations in the Democratic Republic of the Congo.</title>
      <link>https://escholarship.org/uc/item/53p091gw</link>
      <description>&lt;h4&gt;Background&lt;/h4&gt;Historically, the Democratic Republic of the Congo (DRC) has faced the greatest public health burden from mpox, including more than 70 000 probable cases from 1 January 2024 to 2 February 2025. However, there has been a relative paucity of investigation focused on mpox community engagement in DRC, including assessments of disease knowledge and risk perception.&lt;h4&gt;Methods&lt;/h4&gt;Given the ongoing Clade I mpox public health emergency of international concern, and the linkage between sustained human-to-human transmission and dense sexual networks, we sought to investigate mpox knowledge and sexual behaviours among key populations. Between 20 March 2024 and 25 August 2024, we recruited 2794 participants distributed across Kinshasa, Kwango and North Kivu provinces, with a focus in urban centres where mpox risk was considered high.&lt;h4&gt;Results&lt;/h4&gt;Most participants were considered other at-risk populations (948; 33.9%), followed by men who have sex with men (MSM, 828;...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/53p091gw</guid>
      <pubDate>Fri, 22 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Lemaille, Candice</name>
      </author>
      <author>
        <name>Halbrook, Megan</name>
      </author>
      <author>
        <name>Merritt, Sydney</name>
      </author>
      <author>
        <name>Anta, Yvon</name>
      </author>
      <author>
        <name>Lunyanga, Lygie</name>
      </author>
      <author>
        <name>Mukadi, Patrick</name>
      </author>
      <author>
        <name>Hasivirwe Vakaniaki, Emmanuel</name>
      </author>
      <author>
        <name>Kalonji, Thierry</name>
      </author>
      <author>
        <name>Kenye, Michel</name>
      </author>
      <author>
        <name>Kacita, Cris</name>
      </author>
      <author>
        <name>Linsuke, Sylvie</name>
      </author>
      <author>
        <name>Bogoch, Isaac</name>
      </author>
      <author>
        <name>Cevik, Muge</name>
      </author>
      <author>
        <name>Gonsalves, Gregg</name>
      </author>
      <author>
        <name>Hunter, Mikayla</name>
      </author>
      <author>
        <name>Liesenborghs, Laurens</name>
      </author>
      <author>
        <name>Shaw, Souradet</name>
      </author>
      <author>
        <name>Shongo, Robert</name>
      </author>
      <author>
        <name>Hensley, Lisa</name>
      </author>
      <author>
        <name>Hoff, Nicole</name>
      </author>
      <author>
        <name>Rimoin, Anne</name>
      </author>
      <author>
        <name>Mbala-Kingebeni, Placide</name>
      </author>
      <author>
        <name>Kindrachuk, Jason</name>
      </author>
    </item>
    <item>
      <title>Drp1 regulates mitochondrial health and controls skeletal muscle mass through the Erk1/2-Nur77 pathway</title>
      <link>https://escholarship.org/uc/item/3jt0c1rr</link>
      <description>The maintenance of skeletal muscle mass relies on mitochondrial quality control, including balanced dynamics and mitophagy. Dynamin-related protein 1 (Drp1), a central mediator of mitochondrial fission, is essential for these processes, yet its role in muscle mass regulation remains incompletely defined. Here, we show that acute Drp1 deletion in the skeletal muscle increases Parkin-mediated mitochondrial degradation, reduces mitochondrial DNA (mtDNA) content, and leads to severe muscle atrophy. Although dual deletion of Drp1 and Parkin restores mtDNA content, muscle loss persists. Mechanistically, Drp1 loss impairs mitochondrial respiratory chain activity, suppressing extracellular signal-regulated kinase 1/2 (Erk1/2) signaling and down-regulating the nuclear receptor subfamily 4 group A member 1 (Nur77). Pharmacologic β2-adrenergic receptor activation with clenbuterol reactivated Erk1/2, restored Nur77 expression, and rescued muscle atrophy. These findings define a Drp1-Erk1/2-Nur77...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/3jt0c1rr</guid>
      <pubDate>Fri, 22 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>M., Alice</name>
      </author>
      <author>
        <name>Tran, Peter H</name>
      </author>
      <author>
        <name>Yang, Nicole L</name>
      </author>
      <author>
        <name>Ngo, Jennifer</name>
      </author>
      <author>
        <name>Iwasaki, Hirotaka</name>
      </author>
      <author>
        <name>Ren, Wenjuan</name>
      </author>
      <author>
        <name>Livit, Simone</name>
      </author>
      <author>
        <name>Stiles, Linsey</name>
      </author>
      <author>
        <name>Wang, Sarah</name>
      </author>
      <author>
        <name>Ho, Trinity</name>
      </author>
      <author>
        <name>Yim, Emma Y</name>
      </author>
      <author>
        <name>Morrow, Noelle</name>
      </author>
      <author>
        <name>Johnson, Morgan M</name>
      </author>
      <author>
        <name>Cleary, Caroline</name>
      </author>
      <author>
        <name>Zou, Kai</name>
      </author>
      <author>
        <name>Crosbie, Rachelle H</name>
      </author>
      <author>
        <name>Jiang, Yuwei</name>
      </author>
      <author>
        <name>Shirihai, Orian S</name>
      </author>
      <author>
        <name>Wanagat, Jonathan</name>
      </author>
      <author>
        <name>Mahata, Sushil</name>
        <uri>https://orcid.org/0000-0002-9154-0787</uri>
      </author>
      <author>
        <name>Wohlschlegel, James A</name>
        <uri>https://orcid.org/0000-0001-8289-2222</uri>
      </author>
      <author>
        <name>Hevener, Andrea L</name>
      </author>
      <author>
        <name>Zhou, Zhenqi</name>
      </author>
    </item>
    <item>
      <title>New age of Lupus Nephritis: Updates in guidelines, biomarkers, and therapies.</title>
      <link>https://escholarship.org/uc/item/5jd3h4hq</link>
      <description>Lupus nephritis (LN) is the most common visceral organ manifestation of systemic lupus erythematosus (SLE). It affects approximately 50% of SLE patients, accounting for significant morbidity and mortality especially in ethnic minorities. Building on decades of landmark trials, the field has continued to evolve. The 2024 American College Rheumatology (ACR) Lupus Nephritis guideline represents an important shift toward earlier triple therapy. The guideline also recommends routine proteinuria screening and reaffirms kidney biopsy as the diagnostic gold standard. In parallel, urinary biomarkers are emerging as potential tools to better track infrarenal pathology. Furthermore, the therapeutic pipeline continues to expand with emerging strategies targeting B-cells, cytokine receptors, and co-stimulatory mechanisms. In this article, we review updates from the ACR guideline, the emerging data on urinary biomarkers, and highlight novel targeted therapies in LN.</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5jd3h4hq</guid>
      <pubDate>Thu, 21 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Ibrahim, Malika</name>
        <uri>https://orcid.org/0009-0005-7865-8421</uri>
      </author>
      <author>
        <name>He, Emily</name>
      </author>
      <author>
        <name>Tran, Diana</name>
      </author>
      <author>
        <name>Vundamati, Divya</name>
      </author>
      <author>
        <name>Grossman, Jennifer</name>
      </author>
    </item>
    <item>
      <title>Sleep Duration and Prostate Cancer Risk in the Southern Community Cohort Study</title>
      <link>https://escholarship.org/uc/item/10b309pr</link>
      <description>INTRODUCTION: The relationship between insufficient sleep and prostate cancer incidence is unclear. Our goal was to investigate the association of sleep duration, restless sleep, and prostate cancer incidence and aggressiveness, and whether race influences any sleep-prostate cancer association.
METHODS: The Southern Community Cohort Study (SCCS) recruited study participants from 12 Southeastern states from 2002 to 2009. The cohort included nearly 35,000 males, predominantly African American (AA, 67%). Sleep exposures were measured via a baseline questionnaire at enrollment, which captured weekday and weekend sleep duration, weighted average sleep duration, and restless sleep. We used Cox proportional hazards models and multinomial logistic regression models to estimate associations between sleep and prostate cancer incidence and aggressiveness.
RESULTS: During follow-up (median 10.9 years), 1345 men developed prostate cancer. Shorter sleep duration (&amp;lt; 6 h), in comparison to...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/10b309pr</guid>
      <pubDate>Thu, 21 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Anukam, Danica C</name>
      </author>
      <author>
        <name>Nianogo, Roch A</name>
      </author>
      <author>
        <name>Arah, Onyebuchi A</name>
        <uri>https://orcid.org/0000-0002-9067-1697</uri>
      </author>
      <author>
        <name>Boutros, Paul C</name>
      </author>
      <author>
        <name>Rao, Jianyu</name>
      </author>
      <author>
        <name>Fowke, Jay H</name>
      </author>
      <author>
        <name>Zhang, Zuo‐Feng</name>
        <uri>https://orcid.org/0000-0002-4669-3995</uri>
      </author>
    </item>
    <item>
      <title>PFKM governs metabolic shifts throughout skeletal muscle differentiation</title>
      <link>https://escholarship.org/uc/item/84b6w504</link>
      <description>Metabolism is known to influence cell identity, but the underlying mechanisms remain unclear. Here we reveal spatiotemporal dynamics of phosphofructokinase 1 (PFK1), a key glycolytic enzyme, within the skeletal muscle lineage. The expression of PFKM (the muscle isoform of PFK1) is low in muscle stem cells and increases during differentiation. Mechanistically, Wnt signalling rapidly induces lysosomal degradation of PFKM through a methyl arginine degron motif, which gets selectively methylated by the protein arginine methyltransferase (PRMT1) and delivered to lysosomes through microautophagy. PFKM degradation shifts glucose metabolism from glycolysis to the pentose phosphate pathway. PFKM overexpression increases glycolysis and promotes differentiation into terminally differentiated myofibres. On the other hand, PFKM knockdown blunts differentiation, which can be rescued by supplementation with the downstream glycolytic intermediate 3-phosphoglycerate. In sum, our findings highlight...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/84b6w504</guid>
      <pubDate>Mon, 18 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Campos, Melissa</name>
      </author>
      <author>
        <name>Nguyen, Steven T</name>
      </author>
      <author>
        <name>Kong, Xiangduo</name>
      </author>
      <author>
        <name>Yang, Ying</name>
      </author>
      <author>
        <name>Watson, Richard L</name>
        <uri>https://orcid.org/0000-0002-8931-9370</uri>
      </author>
      <author>
        <name>Gromova, Anastasia</name>
      </author>
      <author>
        <name>Livelo, Catherine R</name>
      </author>
      <author>
        <name>Franco, Carolina N</name>
      </author>
      <author>
        <name>Cabral, Julia E</name>
      </author>
      <author>
        <name>Seabrook, Laurence J</name>
      </author>
      <author>
        <name>Dai, Shengqi</name>
      </author>
      <author>
        <name>Liu, Yingzi</name>
      </author>
      <author>
        <name>Zhou, Mingqi</name>
        <uri>https://orcid.org/0009-0007-7643-7873</uri>
      </author>
      <author>
        <name>Hanse, Eric A</name>
      </author>
      <author>
        <name>Sumigray, Kaelyn</name>
      </author>
      <author>
        <name>La Spada, Albert R</name>
      </author>
      <author>
        <name>Seldin, Marcus M</name>
        <uri>https://orcid.org/0000-0001-8026-4759</uri>
      </author>
      <author>
        <name>Plikus, Maksim V</name>
      </author>
      <author>
        <name>Nicholas, Dequina A</name>
      </author>
      <author>
        <name>McNulty, Reginald</name>
      </author>
      <author>
        <name>Kong, Mei</name>
        <uri>https://orcid.org/0000-0001-8139-2349</uri>
      </author>
      <author>
        <name>Yokomori, Kyoko</name>
      </author>
      <author>
        <name>Albrecht, Lauren V</name>
      </author>
    </item>
    <item>
      <title>Improving Primary Healthcare for Elderly Patients: How Chronic Disease Management Intensity Makes a Difference</title>
      <link>https://escholarship.org/uc/item/8jk7p9nh</link>
      <description>Background: Since 2009, China has implemented a chronic disease management program within primary healthcare (PHC) institutions in response to challenges posed by an aging population. However, the effectiveness of the program has been reported as mixed, likely due to variations in PHC physicians’ efforts and the support they received from the health system and community. This multi-sector engagement was conceptualized as management intensity in this study, and its impact on the program’s effectiveness was evaluated. Methods: This study analyzed 60 885 patients under the chronic disease management program in Yuhuan, Zhejiang province, as of 2023. Management intensity, the primary predictor, was quantified by township-level residual measured based on patients’ length of follow-up after eliminating patient demographics. This approach removed the portion of follow-up length attributable to individual characteristics, leaving the residual serving as a purified exposure variable for...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/8jk7p9nh</guid>
      <pubDate>Wed, 6 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Peng, Jia</name>
      </author>
      <author>
        <name>Liang, Di</name>
      </author>
      <author>
        <name>Prasad, Shailendra</name>
      </author>
      <author>
        <name>Kane, Sumit</name>
      </author>
      <author>
        <name>Zhang, Weijun</name>
      </author>
      <author>
        <name>Wu, Yuxia</name>
      </author>
      <author>
        <name>Huang, Jiayan</name>
      </author>
      <author>
        <name>Luo, Yongsong</name>
      </author>
      <author>
        <name>Dong, Yin</name>
      </author>
    </item>
    <item>
      <title>Dissemination, adaptation, and uptake of patient-facing materials to improve care coordination in primary care</title>
      <link>https://escholarship.org/uc/item/5zr7911b</link>
      <description>Objective: We sought to improve patients' experience of care coordination by promoting the uptake of patient-facing tools with evidence of sustained use in Veterans Affairs (VA) primary care clinics. We disseminated tools, adapted and improved tools in response to feedback, and tracked real-world uptake.
Methods: We conducted outreach to leadership and frontline providers at local, regional, and national levels. We collaborated with frontline providers and veteran patients using human-centered design approaches to guide tool adaptation. We assessed dissemination and real-world uptake through website analytics and QR code tracking.
Results: Tools included paper pamphlets that explained care processes, provided contact information, and answered frequently asked questions. Feedback resulted in use of larger fonts; pictures and colors; less dense text; and QR codes. Discussions led to development of new tools addressing current challenges coordinating care with VA-paid community providers....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/5zr7911b</guid>
      <pubDate>Wed, 6 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>O'Hanlon, Claire E</name>
      </author>
      <author>
        <name>Barnard, Jenny M</name>
      </author>
      <author>
        <name>Rose, Danielle E</name>
      </author>
      <author>
        <name>Stockdale, Susan E</name>
      </author>
      <author>
        <name>Chang, Evelyn T</name>
      </author>
      <author>
        <name>Yano, Elizabeth M</name>
      </author>
      <author>
        <name>Ganz, David A</name>
        <uri>https://orcid.org/0009-0004-8512-1641</uri>
      </author>
    </item>
    <item>
      <title>p21+TREM2+ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease</title>
      <link>https://escholarship.org/uc/item/2z8359hb</link>
      <description>Cellular senescence drives chronic sterile inflammation during aging via the senescence-associated secretory phenotype, yet the senescent cell types responsible are poorly defined. Macrophages share multiple features of senescence, including inflammatory secretion, yet whether macrophages can adopt a senescent state remains unclear. Here we identify p21⁺Trem2⁺ senescent macrophages as a major source of inflammaging, using primary mouse and human macrophage models of DNA damage and cholesterol-induced senescence characterized by multi-omic profiling. We found that senescent macrophages exhibit a distinctive p21-TREM2 expression profile and senescence-associated secretory phenotype, driven in part by type I interferon signaling via cytosolic mitochondrial DNA. We also found that senescent macrophage accumulation occurs in aging, metabolic dysfunction-associated steatotic liver disease mouse livers, and is enriched in human cirrhotic liver tissue. Finally, senolytic treatment targeting...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2z8359hb</guid>
      <pubDate>Wed, 6 May 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Salladay-Perez, Ivan A</name>
      </author>
      <author>
        <name>Avila, Itzetl</name>
      </author>
      <author>
        <name>Estrada, Lizeth</name>
      </author>
      <author>
        <name>Alexandru, Andreea C</name>
      </author>
      <author>
        <name>Ponce, Cristian</name>
      </author>
      <author>
        <name>Dhingra, Anika</name>
      </author>
      <author>
        <name>Torres, Grasiela</name>
      </author>
      <author>
        <name>Deng, Christina Y</name>
      </author>
      <author>
        <name>Hegde, Ronak</name>
      </author>
      <author>
        <name>Gensheimer, Julia</name>
      </author>
      <author>
        <name>Kale, Abhijit</name>
      </author>
      <author>
        <name>Heckenbach, Indra</name>
      </author>
      <author>
        <name>Hui, Simon</name>
      </author>
      <author>
        <name>Edillor, Chantle</name>
      </author>
      <author>
        <name>Soto, Jose A</name>
      </author>
      <author>
        <name>Napior, Alexander J</name>
      </author>
      <author>
        <name>Little, Isaiah</name>
      </author>
      <author>
        <name>Larsen, Mark</name>
      </author>
      <author>
        <name>Rose, Jacob</name>
      </author>
      <author>
        <name>Farahi, Lia</name>
      </author>
      <author>
        <name>Lopez Gonzalez, Edwin DJ</name>
      </author>
      <author>
        <name>Krieger, Matthew R</name>
      </author>
      <author>
        <name>Chowdhury, Kushan</name>
      </author>
      <author>
        <name>Sharma, Mridul</name>
      </author>
      <author>
        <name>Jiang, Yuming</name>
      </author>
      <author>
        <name>Williams, Kevin</name>
      </author>
      <author>
        <name>Scheibye-Knudsen, Morten</name>
      </author>
      <author>
        <name>Koehler, Carla M</name>
        <uri>https://orcid.org/0000-0001-8685-2412</uri>
      </author>
      <author>
        <name>Meyer, Jesse G</name>
      </author>
      <author>
        <name>Mack, Julia J</name>
        <uri>https://orcid.org/0000-0002-9239-8436</uri>
      </author>
      <author>
        <name>Brenner, Charles</name>
      </author>
      <author>
        <name>Bensinger, Steven J</name>
      </author>
      <author>
        <name>Lagger, Cyril</name>
      </author>
      <author>
        <name>de Magalhães, João Pedro</name>
      </author>
      <author>
        <name>Schilling, Birgit</name>
      </author>
      <author>
        <name>Singh, Rajat</name>
      </author>
      <author>
        <name>Verdin, Eric</name>
      </author>
      <author>
        <name>Lusis, Aldons J</name>
        <uri>https://orcid.org/0000-0001-9013-0228</uri>
      </author>
      <author>
        <name>Covarrubias, Anthony J</name>
      </author>
    </item>
    <item>
      <title>An Innovative Approach to Enhanced Care Management for High-Need Pediatric Medicaid Members: Retrospective Cohort Study.</title>
      <link>https://escholarship.org/uc/item/1w22f59j</link>
      <description>&lt;h4&gt;Background&lt;/h4&gt;The California Advancing and Innovating Medi-Cal (CalAIM) initiative supports Enhanced Care Management (ECM) for high-need pediatric populations but published evidence of the impact of ECM in pediatric populations is lacking.&lt;h4&gt;Objective&lt;/h4&gt;We evaluated a novel multidisciplinary care model (Pair Team) for delivering ECM services, focusing on implementation and early outcomes for children and adolescents enrolled in Californias Medicaid program (Medi-Cal).&lt;h4&gt;Methods&lt;/h4&gt;We conducted a retrospective, observational cohort study of Medi-Cal-enrolled children and adolescents who enrolled in Pair Teams program between July 2022 and November 2024. Program engagement, health care engagement, and depressive symptoms were assessed using program data, electronic health records, and prescription data.&lt;h4&gt;Results&lt;/h4&gt;The main cohort included 1294 enrollees with 12 months of follow-up data (mean age 8.9 years, 50.3% (651/1294) female, 81.8% (1058/1294) experiencing homelessness)....</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/1w22f59j</guid>
      <pubDate>Mon, 27 Apr 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Juusola, Jessie</name>
      </author>
      <author>
        <name>Kumar, Shefali</name>
      </author>
      <author>
        <name>Iragavarapu, Meghana</name>
      </author>
      <author>
        <name>Mueller, Luke</name>
      </author>
      <author>
        <name>Batlivala, Neil</name>
      </author>
      <author>
        <name>Ong, Michael</name>
      </author>
      <author>
        <name>Ostrovsky, Andrey</name>
      </author>
      <author>
        <name>Favini, Nathan</name>
      </author>
    </item>
    <item>
      <title>Cost-Effectiveness of Medical Therapy for Heart&amp;nbsp;Failure With Mildly Reduced and Preserved Ejection Fraction</title>
      <link>https://escholarship.org/uc/item/9m65555p</link>
      <description>BACKGROUND: Three medications are now guideline-recommended treatments for heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), however, the cost-effectiveness of these agents in combination has yet to be established.
OBJECTIVES: The purpose of this study was to determine the cost-effectiveness of mineralocorticoid receptor antagonists (MRA), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium glucose co-transporter 2 inhibitors (SGLT2is) in individuals with HFmrEF/HFpEF.
METHODS: Using a 3-state Markov model, we performed a cost-effectiveness study using simulated cohorts of 1,000 patients with HFmrEF and HFpEF. Treatment with 1-, 2-, and 3-drug combinations was modeled. Based on a United States health care sector perspective, outcome data was used to calculate incremental cost-effectiveness ratios (ICERs) in 2023 United States dollars based on a 30-year time horizon.
RESULTS: Treatment with MRA, MRA+SGLT2i, and MRA+SGLT2i+ARNI therapy resulted...</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/9m65555p</guid>
      <pubDate>Thu, 23 Apr 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Dixit, Neal M</name>
      </author>
      <author>
        <name>Truong, Katie P</name>
      </author>
      <author>
        <name>Vaduganathan, Muthiah</name>
      </author>
      <author>
        <name>Ziaeian, Boback</name>
        <uri>https://orcid.org/0000-0001-9787-3649</uri>
      </author>
      <author>
        <name>Fonarow, Gregg C</name>
        <uri>https://orcid.org/0000-0002-3192-8093</uri>
      </author>
    </item>
    <item>
      <title>2025 ACC/AHA Clinical Practice Guidelines Core Principles and Development Process A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
      <link>https://escholarship.org/uc/item/70t1t48p</link>
      <description>2025 ACC/AHA Clinical Practice Guidelines Core Principles and Development Process A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/70t1t48p</guid>
      <pubDate>Thu, 23 Apr 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Otto, Catherine M</name>
      </author>
      <author>
        <name>Abdullah, Abdul R</name>
      </author>
      <author>
        <name>Davis, Leslie L</name>
      </author>
      <author>
        <name>Ferrari, Victor A</name>
      </author>
      <author>
        <name>Fremes, Stephen</name>
      </author>
      <author>
        <name>Mukherjee, Debabrata</name>
      </author>
      <author>
        <name>Prestera, Lauren</name>
      </author>
      <author>
        <name>Ziaeian, Boback</name>
        <uri>https://orcid.org/0000-0001-9787-3649</uri>
      </author>
    </item>
    <item>
      <title>NATIONAL COSTS FOR CARDIOVASCULAR-RELATED HOSPITALIZATIONS AND INPATIENT PROCEDURES IN THE UNITED STATES, 2016-2021</title>
      <link>https://escholarship.org/uc/item/2mv824t3</link>
      <description>NATIONAL COSTS FOR CARDIOVASCULAR-RELATED HOSPITALIZATIONS AND INPATIENT PROCEDURES IN THE UNITED STATES, 2016-2021</description>
      <guid isPermaLink="true">https://escholarship.org/uc/item/2mv824t3</guid>
      <pubDate>Thu, 23 Apr 2026 00:00:00 +0000</pubDate>
      <author>
        <name>Haidar, Amier</name>
        <uri>https://orcid.org/0000-0002-3341-1071</uri>
      </author>
      <author>
        <name>Parikh, Rushi</name>
      </author>
      <author>
        <name>Benharash, Peyman</name>
      </author>
      <author>
        <name>Fonarow, Gregg C</name>
      </author>
      <author>
        <name>Watson, Karol E</name>
      </author>
      <author>
        <name>Ziaeian, Boback</name>
        <uri>https://orcid.org/0000-0001-9787-3649</uri>
      </author>
    </item>
  </channel>
</rss>
